<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Autoimmun Rev</journal-id><journal-id journal-id-type="iso-abbrev">Autoimmun Rev</journal-id><journal-title-group><journal-title>Autoimmunity Reviews</journal-title></journal-title-group><issn pub-type="ppub">1568-9972</issn><issn pub-type="epub">1873-0183</issn><publisher><publisher-name>The Author(s). Published by Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7198427</article-id><article-id pub-id-type="publisher-id">S1568-9972(20)30116-6</article-id><article-id pub-id-type="doi">10.1016/j.autrev.2020.102554</article-id><article-id pub-id-type="publisher-id">102554</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Convalescent plasma in Covid-19: Possible mechanisms of action</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name><surname>Rojas</surname><given-names>Manuel</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0010"><name><surname>Rodr&#x000ed;guez</surname><given-names>Yhojan</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0015"><name><surname>Monsalve</surname><given-names>Diana M.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0020"><name><surname>Acosta-Ampudia</surname><given-names>Yeny</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0025"><name><surname>Camacho</surname><given-names>Bernardo</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0030"><name><surname>Gallo</surname><given-names>Juan Esteban</given-names></name><xref rid="af0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0035"><name><surname>Rojas-Villarraga</surname><given-names>Adriana</given-names></name><xref rid="af0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0040"><name><surname>Ram&#x000ed;rez-Santana</surname><given-names>Carolina</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0045"><name><surname>D&#x000ed;az-Coronado</surname><given-names>Juan C.</given-names></name><xref rid="af0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0050"><name><surname>Manrique</surname><given-names>Rub&#x000e9;n</given-names></name><xref rid="af0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0055"><name><surname>Mantilla</surname><given-names>Ruben D.</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0060"><name><surname>Shoenfeld</surname><given-names>Yehuda</given-names></name><xref rid="af0040" ref-type="aff">h</xref><xref rid="af0045" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au0065"><name><surname>Anaya</surname><given-names>Juan-Manuel</given-names></name><email>juan.anaya@urosario.edu.co</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><aff id="af0005"><label>a</label>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia</aff><aff id="af0010"><label>b</label>Cl&#x000ed;nica del Occidente, Bogota, Colombia</aff><aff id="af0015"><label>c</label>Instituto Distrital de Ciencia Biotecnolog&#x000ed;a e Investigaci&#x000f3;n en Salud, IDCBIS, Bogota, Colombia</aff><aff id="af0020"><label>d</label>Genoma CES, Universidad CES, Medellin, Colombia</aff><aff id="af0025"><label>e</label>Fundaci&#x000f3;n Universitaria de Ciencias de la Salud (FUCS), Bogota, Colombia</aff><aff id="af0030"><label>f</label>Internal Medicine Department, Universidad CES, Medellin, Colombia</aff><aff id="af0035"><label>g</label>Epidemiology and Biostatistics Research Group, Universidad CES, Medellin, Colombia</aff><aff id="af0040"><label>h</label>Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Tel-Aviv University, Tel Aviv, Israel</aff><aff id="af0045"><label>i</label>Laboratory of the Mosaics of Autoimmunity, Saint Petersburg State University, Saint-Petersburg, Russian Federation</aff></contrib-group><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Carrera 26-63-B-51, 110010 Bogota, Colombia. <email>juan.anaya@urosario.edu.co</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>5</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>7</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>5</day><month>5</month><year>2020</year></pub-date><volume>19</volume><issue>7</issue><fpage>102554</fpage><lpage>102554</lpage><history><date date-type="received"><day>11</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Author(s)</copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab0005"><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (<italic>i.e.</italic>, cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.</p></abstract><abstract abstract-type="author-highlights" id="ab0010"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="li0005"><label>&#x02022;</label><p id="p0005">Coronavirus disease 19 (COVID-19) is an emerging viral threat with major repercussions for public health.</p></list-item><list-item id="li0010"><label>&#x02022;</label><p id="p0010">There is not specific treatment for COVID-19.</p></list-item><list-item id="li0015"><label>&#x02022;</label><p id="p0015">Convalescent plasma (CP) emerges as the first option of management for hospitalized patients with COVID-19.</p></list-item><list-item id="li0020"><label>&#x02022;</label><p id="p0020">Transference of neutralizing antibodies helps to control COVID-19 infection and modulates inflammatory response.</p></list-item><list-item id="li0025"><label>&#x02022;</label><p id="p0025">Other plasma components may enhance the antiviral and anti-inflammatory properties of CP.</p></list-item></list></p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>Coronavirus</kwd><kwd>COVID-19</kwd><kwd>SARS-Cov-2</kwd><kwd>Convalescent plasma</kwd><kwd>Cytokines</kwd><kwd>Intravenous immunoglobulins</kwd><kwd>Neutralizing antibodies</kwd><kwd>ACE-2 receptor</kwd></kwd-group><kwd-group id="ks0010"><title>Abbreviations</title><kwd>2019-nCoV, 2019 novel coronavirus</kwd><kwd>ACE-2, Angiotensin converting enzyme-2</kwd><kwd>ADE, Antibody-dependent enhancement</kwd><kwd>BAFF, B cell&#x02013;activating factor</kwd><kwd>BCR, B-cell receptor</kwd><kwd>COVID-19, Coronavirus disease 2019</kwd><kwd>CP, Convalescent plasma</kwd><kwd>DCs, Dendritic cells</kwd><kwd>E, Envelope</kwd><kwd>HIV, Human immunodeficiency virus</kwd><kwd>ICU, Intensive care unit</kwd><kwd>IgG, Immunoglobulin G</kwd><kwd>IgM, Immunoglobulin M</kwd><kwd>IVIg, Intravenous immunoglobulin</kwd><kwd>M, Membrane</kwd><kwd>MERS, Middle East respiratory syndrome</kwd><kwd>MERS-CoV, MERS coronavirus</kwd><kwd>N, Nucleoprotein</kwd><kwd>NAbs, Neutralizing antibodies</kwd><kwd>NAT, Nucleic acid test</kwd><kwd>S1-RBD, Spike1-receptor binding protein</kwd><kwd>SARS, Severe acute respiratory syndrome coronavirus</kwd><kwd>SARS-CoV, SARS coronavirus.</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0030">Viruses of the <italic>Coronaviridae</italic> family have a positive-sense, single strand, RNA structure with 26 to 32 kilobases length [<xref rid="bb0005" ref-type="bibr">1</xref>]. Coronaviruses have been recognized in numerous avian hosts and in several mammals, such bats, camels, mice, cats, dogs and more recently in scaly anteaters [<xref rid="bb0010" ref-type="bibr">[2]</xref>, <xref rid="bb0015" ref-type="bibr">[3]</xref>, <xref rid="bb0020" ref-type="bibr">[4]</xref>]. Most of Coronaviruses are pathogenic to humans but they produce mild symptoms or asymptomatic infections. However, in the last two decades two lethal viruses have emerged within this family: the severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) [<xref rid="bb0025" ref-type="bibr">5</xref>], and the Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) [<xref rid="bb0030" ref-type="bibr">6</xref>]. These are characterized by severe fever (85%), non-productive cough (69%), myalgia (49%) and dyspnea (42%), with a high frequency of admission to intensive care unit (ICU) [<xref rid="bb0025" ref-type="bibr">5</xref>,<xref rid="bb0035" ref-type="bibr">7</xref>].</p><p id="p0035">In December 2019, a new member of the <italic>Coronaviridae</italic> family associated with severe pneumonia was detected in Wuhan, China [<xref rid="bb0040" ref-type="bibr">8</xref>]. Patients showed similar clinical findings to SARS-CoV and MERS-CoV given by high fever, dyspnea, and chest radiographs revealing invasive multilobed lesions [<xref rid="bb0045" ref-type="bibr">9</xref>,<xref rid="bb0050" ref-type="bibr">10</xref>]. The virus was initially termed as 2019 novel coronavirus (2019-nCoV) [<xref rid="bb0040" ref-type="bibr">8</xref>], and it is currently known as SARS-CoV-2 producing the coronavirus disease 2019 (COVID-19). The origin of the virus is unknown, however, a recent study showed that the virus shares 88% identity with bat-derived SARS-like coronaviruses named bat-SL-CoVZC45 and bat-SL-CoVZXC21, suggesting that bats are the most likely reservoir [<xref rid="bb0020" ref-type="bibr">4</xref>]. Interestingly, phylogenetic analysis revealed that SARS-CoV and MERS-CoV were close to COVID-19 in about 79% and 50%, respectively. Recently, it has been discussed that the similar sequence of the virus with human proteins could be deleterious and associated with autoimmune phenomena [<xref rid="bb0055" ref-type="bibr">11</xref>,<xref rid="bb0060" ref-type="bibr">12</xref>]. Although the current situation argues for prompt vaccination strategies, it has been suggested that it would be safer to test cross-reactivity of different viral antigens with those in humans to reduce the probability of autoimmune reactions (<italic>i.e.</italic>, molecular mimicry), especially in individuals with genetic background for autoimmunity [<xref rid="bb0055" ref-type="bibr">11</xref>,<xref rid="bb0065" ref-type="bibr">13</xref>].</p><p id="p0040">Currently, treatment of disease is challenging and the lack of clinical evidence with antiviral agents is the rule. Therapeutic schemes with Lopinavir/Ritonavir failed to prove reduction in overall mortality [<xref rid="bb0070" ref-type="bibr">14</xref>]. A recent randomized controlled trial with Hydroxychloroquine, showed reduction in body temperature and cough remission in the intervention group compared with controls [<xref rid="bb0075" ref-type="bibr">15</xref>]. However, the small sample size and the short period of follow up, preclude conclusions about its efficacy. Other study suggested that Azithromycin plus Hydroxychloroquine may reduce viral load, nonetheless, the clinical response associated with this approach was not evaluated and remains to be defined [<xref rid="bb0080" ref-type="bibr">16</xref>]. This combination was recently associated to worse outcomes when Hydroxychloroquine was administrated at high doses (QTc elongation and higher rates of lethality) [<xref rid="bb0085" ref-type="bibr">17</xref>]. Thus, there is not an effective nor safe medication for the management of COVID-19.</p><p id="p0045">Given the lack of evidence for treatment of COVID-19 and vaccines, classical and historical interventions have remerged as options for the control of disease. That is the case of convalescent plasma (CP), a strategy of passive immunization that has been used in prevention and management of infectious diseases since early 20th century [<xref rid="bb0090" ref-type="bibr">18</xref>]. The CP is obtained using apheresis in survivors with prior infections caused by pathogens of interest in whom antibodies against the causal agent of disease are developed. The major target is to neutralize the pathogen for its eradication [<xref rid="bb0095" ref-type="bibr">19</xref>]. Given its rapid obtaining, CP has been considered as an emergency intervention in several pandemics, including the Spanish flu, SARS-CoV, West Nile virus, and more recently, Ebola virus [<xref rid="bb0100" ref-type="bibr">[20]</xref>, <xref rid="bb0105" ref-type="bibr">[21]</xref>, <xref rid="bb0110" ref-type="bibr">[22]</xref>, <xref rid="bb0115" ref-type="bibr">[23]</xref>, <xref rid="bb0120" ref-type="bibr">[24]</xref>]. CP early administered after symptoms onset showed a reduction in mortality compared with placebo or no therapy in severe acute respiratory infections of viral etiology like influenza and SARS-CoV, however, a similar response in Ebola virus disease was not observed [<xref rid="bb0100" ref-type="bibr">20</xref>,<xref rid="bb0125" ref-type="bibr">25</xref>].</p><p id="p0050">During apheresis, in addition to neutralizing antibodies (NAbs), other proteins such as anti-inflammatory cytokines, clotting factors, natural antibodies, defensins, pentraxins and other undefined proteins are obtained from donors [<xref rid="bb0130" ref-type="bibr">26</xref>]. In this sense, transfusion of CP to infected patients may provide further benefits such as immunomodulation <italic>via</italic> amelioration of severe inflammatory response [<xref rid="bb0135" ref-type="bibr">27</xref>]. The latter could be the case of COVID-19 in which an over-activation of the immune system may come with systemic hyper-inflammation or &#x0201c;cytokine storm&#x0201d; driven by IL-1&#x003b2;, IL-2, IL-6, IL-17, IL-8, TNF&#x003b1; and CCL2. This inflammatory reaction may perpetuate pulmonary damage entailing fibrosis and reduction of pulmonary capacity [<xref rid="bb0140" ref-type="bibr">28</xref>,<xref rid="bb0145" ref-type="bibr">29</xref>]. Herein, we propose the likely beneficial mechanisms of administering CP to patients with COVID-19 and provide a summary of evidence of this strategy in the current pandemic. At the proof stage of this article there were 56 clinical trials registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov" id="ir0005">www.clinicaltrials.gov</ext-link>, including ours (<ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04332835" id="ir0010">NCT04332835</ext-link>, <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04332380" id="ir0015">NCT04332380</ext-link>), in which the role of CP in COVID-19 will be evaluated.</p></sec><sec id="s0010"><label>2</label><title>Production and composition</title><sec id="s0015"><label>2.1</label><title>Historical perspective</title><p id="p0055">The principle of CP infusion was established in 1880 when it was shown that immunity against diphtheria relied on existing antibodies in blood from animals intentionally immunized with non-lethal doses of toxins, that could be transferred to animals suffering from active infections [<xref rid="bb0150" ref-type="bibr">30</xref>,<xref rid="bb0155" ref-type="bibr">31</xref>]. Then, it was recognized that immune plasma not only neutralizes the pathogen, but also provides passive immunomodulatory properties that allow the recipient to control the excessive inflammatory cascade induced by several infectious agents or sepsis [<xref rid="bb0130" ref-type="bibr">26</xref>,<xref rid="bb0155" ref-type="bibr">31</xref>]. In the early 1950s, purification and concentration of immunoglobulins from healthy donors or recovered patients provided an option to treat serious infectious diseases as well as immune conditions including primary immunodeficiencies, allergies, and autoimmune diseases [<xref rid="bb0150" ref-type="bibr">30</xref>,<xref rid="bb0160" ref-type="bibr">32</xref>,<xref rid="bb0165" ref-type="bibr">33</xref>].</p><p id="p0060">Several convalescent blood products such as intravenous immunoglobulins (IVIg) and polyclonal or monoclonal antibodies have been developed to treat infectious conditions [<xref rid="bb0090" ref-type="bibr">18</xref>]. However, in situations of emergency, they are difficult and expensive to produce, and may not yield an appropriate infectious control. Thus, the use of CP has been widely used in different outbreaks as the first therapeutic option given the lack of effective medications or vaccines, and often as last chance or experimental treatment [<xref rid="bb0130" ref-type="bibr">26</xref>].</p><p id="p0065">From the Spanish influenza to the current pandemic caused by SARS-Cov-2, it has been observed that the use of CP significantly reduces the case fatality rates. That is the case of Influenza A (H1N1) pdm09, Spanish Influenza A (H1N1), and SARS-CoV infections in which the use of CP was associated to reduction in fatality rates, mortality (<xref rid="t0005" ref-type="table">Table 1</xref>
) [<xref rid="bb0025" ref-type="bibr">5</xref>,<xref rid="bb0170" ref-type="bibr">[34]</xref>, <xref rid="bb0175" ref-type="bibr">[35]</xref>, <xref rid="bb0180" ref-type="bibr">[36]</xref>, <xref rid="bb0185" ref-type="bibr">[37]</xref>, <xref rid="bb0190" ref-type="bibr">[38]</xref>, <xref rid="bb0195" ref-type="bibr">[39]</xref>, <xref rid="bb0200" ref-type="bibr">[40]</xref>, <xref rid="bb0205" ref-type="bibr">[41]</xref>, <xref rid="bb0210" ref-type="bibr">[42]</xref>, <xref rid="bb0215" ref-type="bibr">[43]</xref>, <xref rid="bb0220" ref-type="bibr">[44]</xref>, <xref rid="bb0225" ref-type="bibr">[45]</xref>,<xref rid="bib551" ref-type="bibr">111</xref>], and mild adverse events (<xref rid="t0010" ref-type="table">Table 2</xref>
) [<xref rid="bb0125" ref-type="bibr">25</xref>,<xref rid="bb0230" ref-type="bibr">[46]</xref>, <xref rid="bb0235" ref-type="bibr">[47]</xref>, <xref rid="bb0240" ref-type="bibr">[48]</xref>, <xref rid="bb0245" ref-type="bibr">[49]</xref>]. Furthermore, the use of CP in other coronaviruses such as SARS-CoV, reduced days of hospital stay in critically ill patients [<xref rid="bb0210" ref-type="bibr">42</xref>,<xref rid="bb0250" ref-type="bibr">50</xref>]. In relation to the use of mechanical ventilation, in Influenza A (H1N1) pdm09, and avian influenza A (H5N1), administration of CP reduced the duration of invasive ventilation [<xref rid="bb0235" ref-type="bibr">47</xref>,<xref rid="bb0255" ref-type="bibr">51</xref>]. In addition, it has been described that the use of CP in SARS-CoV and avian influenza A (H5N1) decreased the viral load in the respiratory tract [<xref rid="bb0230" ref-type="bibr">46</xref>,<xref rid="bb0245" ref-type="bibr">49</xref>]. Currently, CP used in patients with COVID-19 demonstrated to reduce viral load and improve clinical condition [<xref rid="bb0190" ref-type="bibr">38</xref>,<xref rid="bb0195" ref-type="bibr">39</xref>]. However, it is necessary to conduct randomized controlled trials to confirm the usefulness of this intervention in both hospitalized patients with mild/severe symptoms and those in ICU.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Convalescent plasma in patients with respiratory infection by Coronavirus (SARS, MERS, and COVID-19).</p></caption><alt-text id="al0010">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Author</th><th>Country</th><th>Study design</th><th>Viral Etiology</th><th>Diagnosis</th><th>Individuals included</th><th>Non-CP treatment</th><th>Previous clinical state CP</th><th>Dose protocol CP</th><th>Intervention</th><th>Outcomes</th><th>Mortality</th></tr></thead><tbody><tr><td>Zhang et al. (2020) <xref rid="bib551" ref-type="bibr">[111]</xref></td><td>China</td><td>Case series</td><td>COVID-19</td><td>RT-PCR</td><td>Intervention: 4</td><td>Lopinavir/Ritonavir, Interferon alpha-2b, oseltamivir, Ribavirin</td><td>Clinical deterioration</td><td>Unknown</td><td>200&#x02013;400 mL in one or two consecutive transfusions. A patient received 2,400 mL divided in eight consecutive transfusions</td><td>Clinical recovery and discharge from hospital</td><td>0% intervention group</td></tr><tr><td>Shen et al. (2020) [<xref rid="bb0190" ref-type="bibr">38</xref>]</td><td>China</td><td>Case series</td><td>COVID-19</td><td>RT-PCR</td><td>Intervention: 5</td><td>All patients received antiviral management during treatment.</td><td>Clinical deterioration</td><td>CP from the same donor</td><td>CP 200&#x02013;250&#x000a0;mL two consecutive transfusions CP 200&#x000a0;mL single dose</td><td>Improvement in viral load and increase in antibodies</td><td>0% intervention group</td></tr><tr><td>Duan et al. (2020) [<xref rid="bb0195" ref-type="bibr">39</xref>]</td><td>China</td><td>Clinical trial</td><td>COVID-19</td><td>RT-PCR</td><td>Intervention: 19</td><td>Ribavirin, Cefoperazone, Levoflaxacin, Methylprednisolone, Interferon, Peramivir, Caspofungin.</td><td>Clinical deterioration</td><td>CP from the same donor</td><td>CP 200&#x000a0;mL single dose</td><td>Viral load improvement and lung imaging</td><td>Reduction of viral load and improvement in lung images</td></tr><tr><td>Ye et al. (2020) [<xref rid="bb0185" ref-type="bibr">37</xref>]</td><td>China</td><td>Case series</td><td>COVID-19</td><td>RT-PCR</td><td>Intervention: 6</td><td>Not reported</td><td>Clinical deterioration</td><td>Unknown</td><td>CP 200&#x02013;250&#x000a0;mL two consecutive transfusions</td><td>Reduction of viral load and increase of SARS-CoV-2 IgG and IgM antibodies</td><td>0% intervention group</td></tr><tr><td>Anh et al. (2020) [<xref rid="bb0170" ref-type="bibr">34</xref>]</td><td>South Korea</td><td>Case report</td><td>COVID-19</td><td>RT-PCR</td><td>Intervention: 2</td><td>Lopinavir/Ritonavir, hydroxychloroquine and empirical antibiotics</td><td>Clinical deterioration</td><td>Unknown</td><td>Unknown</td><td>Reduction of viral load and increase of SARS-CoV-2 IgG and IgM antibodies</td><td>0% intervention group</td></tr><tr><td rowspan="2">Soo <italic>et al</italic> (2004) [<xref rid="bb0200" ref-type="bibr">40</xref>]</td><td rowspan="2">China</td><td rowspan="2">Retrospective comparison of cases</td><td rowspan="2">SARS-CoV</td><td rowspan="2">CDC Case Definition</td><td rowspan="2">Intervention: 19, control: 21</td><td>Intervention Group: Ribavirin, 3 doses Methylprednisolone (1 &#x02219; 5&#x000a0;g).</td><td rowspan="2">Clinical deterioration</td><td rowspan="2">Unknown</td><td rowspan="2">CP 200&#x02013;400&#x000a0;mL&#x000a0;days 11 and 42 after the onset of symptoms</td><td rowspan="2">Mortality, length of hospital stay, adverse events</td><td rowspan="2">23% reduction (<italic>p</italic>&#x000a0;=&#x000a0;.03)</td></tr><tr><td>Control group: Ribavirin, 4 or more doses of Methylprednisolone (1 &#x02219; 5&#x000a0;g).</td></tr><tr><td>Cheng <italic>et al</italic> (2005) [<xref rid="bb0205" ref-type="bibr">41</xref>]</td><td>China</td><td>Case series</td><td>SARS-CoV</td><td>CDC case definition and serology</td><td>Intervention: 80</td><td>Unknown</td><td>Clinical deterioration</td><td>Unknown</td><td>CP 279&#x000a0;mL per day 14</td><td>Mortality, length of hospital stay</td><td>12.5% intervention group</td></tr><tr><td>Nie et al. (2003) [<xref rid="bb0025" ref-type="bibr">5</xref>]</td><td>China</td><td>Case series</td><td>SARS-CoV</td><td>Unknown</td><td>Intervention: 40</td><td>Unknown</td><td>Unknown</td><td>Unknown</td><td>CP unknown dose</td><td>Mortality</td><td>0% intervention group</td></tr><tr><td>Yeh <italic>et al</italic> (2005) [<xref rid="bb0210" ref-type="bibr">42</xref>]</td><td>Taiwan</td><td>Case series</td><td>SARS-CoV</td><td>Serology</td><td>Intervention: 3</td><td>Ribavirin, Moxifloxacin, Methylprednisolone</td><td>Clinical deterioration</td><td>Unknown</td><td>CP unknown dose on day 11 of symptom onset</td><td>Mortality, antibodies, viral load, adverse events</td><td>0% intervention group</td></tr><tr><td>Zhou et al. (2003) [<xref rid="bb0215" ref-type="bibr">43</xref>]</td><td>China</td><td>Case series</td><td>SARS-CoV</td><td>CDC case definition</td><td>Intervention: 1 control: 28</td><td>All patients received Ribavirin, Azithromycin, Levofloxacin, Steroids, Mechanical ventilation.</td><td>Vulnerable or comorbid older adults</td><td>Unknown</td><td>CP 50&#x000a0;mL single dose on day 17 of symptom onset</td><td>Mortality, length of hospital stay</td><td>7% reduction (<italic>p</italic>&#x000a0;=&#x000a0;.93)</td></tr><tr><td>Kong (2003) [<xref rid="bb0220" ref-type="bibr">44</xref>]</td><td>China (Hong Kong)</td><td>Case report</td><td>SARS-CoV</td><td>Clinical Diagnosis</td><td>Intervention: 1</td><td>Antivirals, Steroids, Ventilation</td><td>Clinical deterioration</td><td>CP from the same donor</td><td>CP 250&#x000a0;mL 2 doses day 7 of the onset of symptoms</td><td>Mortality</td><td>0% intervention group</td></tr><tr><td>Wong <italic>et al</italic> (2003) [<xref rid="bb0225" ref-type="bibr">45</xref>]</td><td>China (Hong Kong)</td><td>Case report</td><td>SARS-CoV</td><td>WHO case definition</td><td>Intervention: 1</td><td>Ribavirin, Oseltamivir, Cefotaxime, Levofloxacin</td><td>Clinical deterioration</td><td>CP from the same donor</td><td>200&#x000a0;mL CP on day 14 of symptom onset</td><td>Mortality</td><td>0% intervention group</td></tr><tr><td>Ko et al. (2018) [<xref rid="bb0175" ref-type="bibr">35</xref>]</td><td>South Korea</td><td>Case series</td><td>MERS-CoV</td><td>RT-PCR</td><td>Intervention: 3</td><td>Steroids</td><td>Clinical deterioration</td><td>Unknown</td><td>CP unspecified dose</td><td>Antibody titers</td><td>0% intervention group</td></tr></tbody></table><table-wrap-foot><fn><p>CDC: Centers for disease control and prevention; COVID-19: Coronavirus disease 2019; CP: Convalescent plasma; MERS-CoV: Middle East respiratory syndrome coronavirus; mL: Millilitres; IgM: Immunoglobulin M; IgG: Immunoglobulin G; NA: Not available; RT PCR: Real-time polymerase chain reaction; SARS-CoV: Severe acute respiratory syndrome coronavirus; WHO: World health organization. Taken and modified from [<xref rid="bb0100" ref-type="bibr">20</xref>].</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Associated adverse events to convalescent plasma in different epidemics.</p></caption><alt-text id="al0015">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Author</th><th>Country</th><th>Viral etiology</th><th>Adverse events</th></tr></thead><tbody><tr><td>Zhang; et al. (2020) <xref rid="bib551" ref-type="bibr">[111]</xref></td><td>China</td><td>COVID-19</td><td>None</td></tr><tr><td>Shen et al. (2020) [<xref rid="bb0190" ref-type="bibr">38</xref>]</td><td>China</td><td>COVID-19</td><td>None</td></tr><tr><td>Duan et al. (2020) [<xref rid="bb0195" ref-type="bibr">39</xref>]</td><td>China</td><td>COVID-19</td><td>Self-limited facial erythema in 2/10 patients. No major adverse events.</td></tr><tr><td>Ye et al. (2020) [<xref rid="bb0185" ref-type="bibr">37</xref>]</td><td>China</td><td>COVID-19</td><td>None</td></tr><tr><td>Anh et al. (2020) [<xref rid="bb0170" ref-type="bibr">34</xref>]</td><td>South Korea</td><td>COVID-19</td><td>None</td></tr><tr><td>Soo et al (2004) [<xref rid="bb0200" ref-type="bibr">40</xref>]</td><td>China</td><td>SARS-CoV</td><td>None</td></tr><tr><td>Cheng et al (2005) [<xref rid="bb0205" ref-type="bibr">41</xref>]</td><td>China</td><td>SARS-CoV</td><td>None</td></tr><tr><td>Nie et al. (2003) [<xref rid="bb0025" ref-type="bibr">5</xref>]</td><td>China</td><td>SARS-CoV</td><td>None</td></tr><tr><td>Yeh et al (2005) [<xref rid="bb0210" ref-type="bibr">42</xref>]</td><td>Taiwan</td><td>SARS-CoV</td><td>None</td></tr><tr><td>Zhou et al. (2003) [<xref rid="bb0215" ref-type="bibr">43</xref>]</td><td>China</td><td>SARS-CoV</td><td>None</td></tr><tr><td>Kong et al. (2003) [<xref rid="bb0220" ref-type="bibr">44</xref>]</td><td>China</td><td>SARS-CoV</td><td>None</td></tr><tr><td>Wong et al (2003) [<xref rid="bb0225" ref-type="bibr">45</xref>]</td><td>China</td><td>SARS-CoV</td><td>None</td></tr><tr><td>Ko et al. (2018) [<xref rid="bb0175" ref-type="bibr">35</xref>]</td><td>South Korea</td><td>MERS-CoV</td><td>None</td></tr><tr><td>Van Griensven et al. (2016) [<xref rid="bb0125" ref-type="bibr">25</xref>]</td><td>Guinea</td><td>Ebola</td><td>Nausea, skin erythema, fever. No major adverse events.</td></tr><tr><td>Hung et al. (2011) [<xref rid="bb0230" ref-type="bibr">46</xref>]</td><td>China</td><td>Influenza A(H1N1)</td><td>None</td></tr><tr><td>Chan et al. (2010) [<xref rid="bb0235" ref-type="bibr">47</xref>]</td><td>China</td><td>Influenza A(H1N1)</td><td>None</td></tr><tr><td>Yu et al. (2008) [<xref rid="bb0240" ref-type="bibr">48</xref>]</td><td>China</td><td>Influenza A(H5N1)</td><td>None</td></tr><tr><td>Kong et al. (2006) [<xref rid="bb0245" ref-type="bibr">49</xref>]</td><td>China</td><td>Influenza A(H5N1)</td><td>None</td></tr></tbody></table><table-wrap-foot><fn><p>COVID-19: Coronavirus disease 2019; MERS-CoV: Middle East respiratory syndrome coronavirus; SARS-CoV: Severe acute respiratory syndrome coronavirus.</p></fn></table-wrap-foot></table-wrap></p><p id="p0070">The safety of the use of CP is another issue that has been historically relevant in epidemics. Currently, evidence exists of the safety of CP in situations of emergency (<xref rid="t0010" ref-type="table">Table 2</xref>). In epidemics of Influenza A (H1N1), SARS-CoV and MERS-CoV, studies did not find any adverse event associated to CP administration. In the case of Ebola, CP administration was associated with mild adverse reactions such as nausea, skin erythema, and fever [<xref rid="bb0125" ref-type="bibr">25</xref>]. In COVID-19, reports have shown that administration of CP is safe, and it was not associated with major adverse events. Thus, due to tolerability and potential efficacy, CP is a good candidate to be evaluated as a therapeutic option to control the current pandemic.</p></sec><sec id="s0020"><label>2.2</label><title>Acquisition and plasma composition</title><p id="p0075">The convalescent donors must undergo standard pre-donation assessment to ensure compliance with current regulations regarding plasma donation [<xref rid="bb0260" ref-type="bibr">52</xref>]. Currently, convalescent donors between 18 and 65 are considered as subjects without infectious symptomatology and a negative test for COVID-19 after 14&#x000a0;days of recovery. These tests must be repeated 48&#x000a0;h later and at the moment of donation [<xref rid="bb0195" ref-type="bibr">39</xref>,<xref rid="bb0260" ref-type="bibr">52</xref>]. Donors from endemic areas for tropical diseases (<italic>e.g.</italic>, malaria) should be excluded. In addition to molecular tests, it is critical to recognize the emotional situation, to explore susceptibilities, and guarantee not exploitation of donors [<xref rid="bb0265" ref-type="bibr">53</xref>].</p><p id="p0080">Apheresis is the recommended procedure to obtain plasma. This procedure is based on a continuous centrifugation of blood from donor to allow a selective collection plasma. The efficiency of this technique is around 400&#x02013;800&#x000a0;mL from a single apheresis donation. This amount of plasma could be storage in units of 200 or 250&#x000a0;mL, and frozen within 24&#x000a0;h of collection to be used in further transfusions [<xref rid="bb0270" ref-type="bibr">54</xref>].</p><p id="p0085">As CP production requires high quality standards, it must be free of any infection, so tests for human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis, human T-cell lymphotropic virus 1 and 2, and <italic>Trypanosoma cruzi</italic> (if living in an endemic area) should be carried out [<xref rid="bb0260" ref-type="bibr">52</xref>,<xref rid="bb0275" ref-type="bibr">55</xref>]. In this sense, the nucleic acid test for HIV and hepatitis viruses is mandatory to guarantee the safety of recipients [<xref rid="bb0280" ref-type="bibr">56</xref>]. Other protocols suggest the inactivation of pathogens with riboflavin or psoralen plus exposure to ultraviolet light to improve safety of CP [<xref rid="bb0285" ref-type="bibr">57</xref>].</p><p id="p0090">There is not a standard transfusion dose of CP. In different studies for coronaviruses the administration of CP ranges between 200 and 500&#x000a0;mL in single or double scheme dosages (<xref rid="t0005" ref-type="table">Table 1</xref>). Currently, the recommendation is to administrate 3&#x000a0;mL/kg per dose in two days [<xref rid="bb0270" ref-type="bibr">54</xref>]. This strategy facilitates the distribution of plasma units (250&#x000a0;mL per unit) and provide a standard option of delivery in public health strategies.</p><p id="p0095">Composition of CP is variable and include a wide variety of blood derive components. Plasma contains a mixture of inorganic salts, organic compounds, water, and more than 1000 proteins. In the latter we found albumin, immunoglobulins, complement, coagulation and antithrombotic factors among others [<xref rid="bb0290" ref-type="bibr">58</xref>] (<xref rid="f0005" ref-type="fig">Fig. 1</xref>A). Interestingly, it is supposed that plasma from healthy donors provides immunomodulatory effects <italic>via</italic> the infusion of anti-inflammatory cytokines and antibodies that blockade complement, inflammatory cytokines and autoantibodies [<xref rid="bb0135" ref-type="bibr">27</xref>]. These factors may influence the immunomodulatory effect of CP in patients with COVID-19 (see below for details).<fig id="f0005"><label>Fig. 1</label><caption><p>Schematic representation of convalescent plasma components and its mechanisms of action. <bold>A.</bold> Main convalescent plasma components. <bold>B.</bold> Antiviral effects of NAbs. IgG and IgM are the main isotypes, although IgA may be also important, particularly in mucosal viral infections. Other non-NAbs may exert a protective effect. The humoral immune response is mainly directed towards spike (S) protein. <bold>C.</bold> Anti-inflammatory effects of CP include network of autoantibodies and control of an overactive immune system (<italic>i.e.</italic>, cytokine storm, Th1/Th17 ratio, complement activation and regulation of a hypercoagulable state) (see text for details). N: Nucleoprotein; M: Membrane; E: Envelope.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p></sec></sec><sec id="s0025"><label>3</label><title>Antiviral mechanisms</title><p id="p0100">NAbs are crucial in virus clearance and have been considered essential in protecting against viral diseases. Passive immunity driven by CP can provide these NAbs that restrain the infection. The efficacy of this therapy has been associated with the concentration of NAbs in plasma from recovered donors <xref rid="bb0125" ref-type="bibr">[25]</xref>, <xref rid="bib552" ref-type="bibr">[112]</xref>. In SARS-CoV and MERS was discovered that NAbs bind to spike1-receptor binding protein (S1-RBD), S1-N-terminal domain and S2, thus inhibiting their entry, limiting viral amplification [<xref rid="bb0295" ref-type="bibr">59</xref>]. Moreover, other antibody-mediated pathways such as complement activation, antibody-dependent cellular cytotoxicity and/or phagocytosis may also promote the therapeutic effect of CP.</p><p id="p0105">Tian et al. [<xref rid="bb0300" ref-type="bibr">60</xref>], showed through ELISA and Biolayer Interferometry Binding that one SARS-CoV-specific antibody, CR3022, bind with COVID-19 RBD and more importantly this antibody did not show any competition with angiotensin converting enzyme-2 (ACE-2) for the binding to COVID-19 RBD. The RBD of COVID-19 varies broadly from the SARS-CoV at the C-terminus residues. Although this difference does not enable COVID-19 to bind ACE-2 receptor, does influence the cross-reactivity of NAbs [<xref rid="bb0300" ref-type="bibr">60</xref>].</p><p id="p0110">A pseudotyped-lentiviral-vector-based neutralization assay to measure specific NAbs in plasma from recovered patients with SARS-CoV-2 showed variations in NAbs titers, approximately 30% of patients did not develop high NAbs titers after infection [<xref rid="bb0305" ref-type="bibr">61</xref>]. These variations are associated with age, lymphocyte count, and C reactive protein levels in blood, suggesting that other components from plasma contribute to the recovery of these patients.</p><p id="p0115">In plasma, in addition to NAbs, there are other protective antibodies, including immunoglobulin G (IgG) and immunoglobulin M (IgM). Non-NAbs that bind to the virus, but do not affect its capacity to replicate, might contribute to prophylaxis and/or recovery improvement [<xref rid="bb0270" ref-type="bibr">54</xref>] (<xref rid="f0005" ref-type="fig">Fig. 1</xref>B).</p><p id="p0120">SARS-CoV infection induces IgG antibodies production against nucleoprotein (N) that can be detected at day 4 after the onset of disease and with seroconversion at day 14 [<xref rid="bb0310" ref-type="bibr">62</xref>]. In SARS infection 89% of the recovered patients, showed IgG-specific and NAbs 2&#x000a0;years post infection [<xref rid="bb0315" ref-type="bibr">63</xref>]. Moreover, the highest concentration of IgM was detected on the ninth day after the onset of disease and class switching to IgG occurred in the second week [<xref rid="bb0320" ref-type="bibr">64</xref>].</p><p id="p0125">Shen et al. [<xref rid="bb0190" ref-type="bibr">38</xref>], showed that recovered donors from COVID-19 infection had SARS-CoV-2&#x02013;specific antibody titers ranging between 1.800 and 16.200 and NAbs titers were between 80 and 480. The plasma obtained from the donors and transfused in the recipients on the same day lead to viral load decreased. After transfusion of CP, the titers of IgG and IgM in the recipients increased in a time-dependent manner. Moreover, presence of NAbs in the recipients played a vital role in the restriction of viral infection. Another study evaluated the kinetics of SARS-CoV-2-specific NAbs development during the course of the disease. The titers of NAbs in patients infected with SARS-CoV-2 were low before day 10 post-disease onset and then increased, with a peak 10 to 15&#x000a0;days after disease onset, remaining stable thereafter in all patients [<xref rid="bb0305" ref-type="bibr">61</xref>].</p></sec><sec id="s0030"><label>4</label><title>Immunomodulation</title><sec id="s0035"><label>4.1</label><title>F(ab&#x000b4;)2 mechanisms</title><p id="p0130">Historically, administration of IVIg has been one of the critical interventions in patients with autoimmune diseases as well as in autoinflammatory diseases, transplantation (<italic>i.e.</italic>, chronic graft <italic>vs.</italic> host disease after marrow transplantation), primary and secondary immunodeficiency, hematologic malignancies among other conditions. Preparation of IVIg includes anti-idiotypic antibodies that blockade autoreactive recipient antibodies [<xref rid="bb0180" ref-type="bibr">36</xref>,<xref rid="bb0325" ref-type="bibr">65</xref>]. This reaction is critical to control autoantibodies in patients with autoimmune diseases. In this sense, a recent report in patients with COVID-19, showed that critically ill patients exhibited positivity for anti-cardiolipin IgA antibodies as well as for anti&#x02013;&#x003b2;2-glycoprotein I IgA and IgG antibodies [<xref rid="bb0330" ref-type="bibr">66</xref>]. This evidence may suggest that CP-COVID-19 may neutralize this type of autoantibodies reducing the odds of suffering from thrombotic events (<italic>i.e.</italic>, antiphospholipid syndrome-like disease), especially in critically ill patients. In the same line, a recent report of a patient with Sj&#x000f6;gren's syndrome and COVID-19 successfully treated with CP may suggest that this strategy is safe and effective in autoimmune conditions [<xref rid="bb0185" ref-type="bibr">37</xref>].</p><p id="p0135">In addition, some antibodies inhibit complement cascade (<italic>i.e.</italic>, C3a and C5a), and limit the formation of immune complexes (<xref rid="f0005" ref-type="fig">Fig. 1</xref>C) [<xref rid="bb0335" ref-type="bibr">67</xref>,<xref rid="bb0340" ref-type="bibr">68</xref>]. Complement-deficient mice with induced SARS-CoV infection showed high viral titers, secretion of inflammatory cytokines and chemokines, and immune cell infiltration within the lung. These results suggest that complement activation largely contribute to systemic inflammation and migration of neutrophils to the lungs, perpetuating tissue damage [<xref rid="bb0345" ref-type="bibr">69</xref>]. Additional studies have shown that IgG transferred by plasma neutralize cytokines such as IL-1&#x003b2; and TNF&#x003b1; [<xref rid="bb0350" ref-type="bibr">70</xref>]. In this sense, passive immunity by infusion of CP-COVID-19 may limit the inflammatory cascade driven by pathogenic antibodies, as well as the cellular damage induced by the complement cascade activation in excessive inflammatory environments.</p><p id="p0140">Antibody-dependent enhancement (ADE) is a mechanism in which the intensity of infection increases in the presence of preexisting poorly NAbs, favoring the replication of virus into macrophages and other cells through interaction with Fc and/or complement receptors [<xref rid="bb0355" ref-type="bibr">71</xref>]. This phenomenon is used by feline coronaviruses, HIV and dengue viruses to take advantage of prior anti-viral humoral immune response to effectively infect host target cells [<xref rid="bb0360" ref-type="bibr">72</xref>,<xref rid="bb0365" ref-type="bibr">73</xref>]. <italic>In vitro</italic> assays with human promonocyte cell lines demonstrated that SARS-CoV ADE was primarily mediated by antibodies against spike proteins, significantly increasing the rate of apoptosis in these cells [<xref rid="bb0365" ref-type="bibr">73</xref>]. This is of major interest in regions in which coronaviruses are endemic. Vaccines development should consider this phenomenon in patients with COVID-19, and administration of CP-COVID-19 in these areas should be conducted with caution since ADE may emerge as a harmful reaction in patients with active infection [<xref rid="bb0370" ref-type="bibr">74</xref>]. If one suspects of this phenomenon following CP-COVID-19 administration, clinicians must promptly notify the health authorities and evaluate the safety according to endemic coronaviruses in the region.</p></sec><sec id="s0040"><label>4.2</label><title>Fc mechanisms</title><p id="p0145">FcRn is a critical regulator of IgG half-life. This receptor works by preventing degradation and clearance of IgG, by a pinocytotic mechanism that allow antibody circulation within the cell for its posterior excretion [<xref rid="bb0325" ref-type="bibr">65</xref>,<xref rid="bb0375" ref-type="bibr">75</xref>]. The FcRn inhibitor rozanolixizumab showed reduction of IgG concentrations in a phase 1 study [<xref rid="bb0380" ref-type="bibr">76</xref>], and it proved to be critical in IVIg catabolism in common variable immunodeficiency patients [<xref rid="bb0385" ref-type="bibr">77</xref>]. It has been demonstrated that saturation of this receptor by IVIg may account as the most likely mechanism to clear autoantibodies in autoimmune conditions by shortening their lifetime [<xref rid="bb0390" ref-type="bibr">[78]</xref>, <xref rid="bb0395" ref-type="bibr">[79]</xref>, <xref rid="bb0400" ref-type="bibr">[80]</xref>]. Whether antibodies play a critical role in COVID-19 pathogenesis stills remain to be elucidated, however, the saturation of FcRn may provide an additional immunomodulatory pathway in patients receiving CP.</p><p id="p0150">Fc&#x003b3; receptors are found in about all immune cells. These receptors are critical factors in modulating or inhibiting activity of immune cells, including lymphocytes [<xref rid="bb0375" ref-type="bibr">75</xref>]. Fc&#x003b3; receptor activation by IgG induces the upregulation of FC&#x003b3;RIIB which has been associated with inhibitory effects. This was demonstrated in B cells, where the upregulation of FC&#x003b3;RIIB was associated with treatment efficacy for acute rejection after kidney transplantation [<xref rid="bb0405" ref-type="bibr">81</xref>], and was a key determinant for IVIg response in patients with Kawasaki disease [<xref rid="bb0410" ref-type="bibr">82</xref>]. It has been suggested that sialylation of this receptor is critical for inhibitory effects in immune cells [<xref rid="bb0415" ref-type="bibr">83</xref>]. However, the study of Th17 cells in autoimmune encephalomyelitis model revealed that this process is dispensable for the immunomodulatory effect of IVIg treatment [<xref rid="bb0420" ref-type="bibr">84</xref>]. Despite these results, CP infusion may help the modulation of immune response <italic>via</italic> Fc&#x003b3; receptors, and merits attention in the current management of COVID-19.</p></sec><sec id="s0045"><label>4.3</label><title>Dendritic cells</title><p id="p0155">Dendritic cells (DCs) are key regulators of innate immunity and work as specialized antigen presenting cells. <italic>In vitro</italic> studies have shown that administration of IVIg may abrogate maturation of DCs, as well as a reduction in the production of IL-12. Interestingly, the production of IL-10 was enhanced [<xref rid="bb0425" ref-type="bibr">85</xref>]. In the study conducted by Sharma et al. [<xref rid="bb0430" ref-type="bibr">86</xref>], authors found that IVIg induced the production of IL-33 that subsequently expands IL-4-producing basophils. In this line, other study found that IVIg could promote the production of IL-4 and IL-13 which correlated with levels of IL-33 [<xref rid="bb0435" ref-type="bibr">87</xref>]. A Th2 cytokine-mediated downregulation of Fc&#x003b3;RIIa and IFN-&#x003b3;R2 was suggested to be the most likely mechanisms for this phenomenon. Recently, it was found that IVIg activates &#x003b2;-catenin in an IgG-sialylation independent manner, which is critical for reducing inflammation [<xref rid="bb0440" ref-type="bibr">88</xref>].</p><p id="p0160">Down regulation of HLA-II and costimulation molecules such CD86, CD80, and CD40 have been reported in DCs after stimulation with IVIg [<xref rid="bb0425" ref-type="bibr">85</xref>]. In patients with systemic lupus erythematosus, which show a high proinflammatory environment, administration of IVIg abrogated IFN-&#x003b1;-mediated maturation [<xref rid="bb0445" ref-type="bibr">89</xref>,<xref rid="bb0450" ref-type="bibr">90</xref>]. All together, data suggest that infusion of plasma from recovered COVID-19 donors may enhance anti-inflammatory properties of DCs, which could be critical in phases of excessive inflammatory stimuli in patients with COVID-19.</p></sec><sec id="s0050"><label>4.4</label><title>T cells</title><p id="p0165">Despite the ability of enhancing Th2 <italic>via</italic> IL-33 in DCs [<xref rid="bb0435" ref-type="bibr">87</xref>], it has been described that IVIg modulates the balance between CD4<sup>+</sup>/CD8<sup>+</sup> T cells, as well as promoting proliferation and survival of Tregs. Treatment with IVIg seems to reduce antigenic presentation of T cells <italic>via</italic> the modulation and inhibition of DCs. This process was independent of FC&#x003b3;RIIB [<xref rid="bb0455" ref-type="bibr">91</xref>], and other reports showed that reduced activation of T cells was independent of IgG sialylation, monocytes or B cells [<xref rid="bb0460" ref-type="bibr">92</xref>].</p><p id="p0170">In addition, patients treated with IVIg showed a reduction in Th1 cells and low levels of IFN&#x003b3; and TNF&#x003b1; with the increase of Th2 cytokines such as IL-4 and IL-10 [<xref rid="bb0465" ref-type="bibr">93</xref>]. Clinically, it has been demonstrated that patients with Influenza A (H1N1) treated with CP exhibited a reduction of IL-6 and TNF&#x003b1; [<xref rid="bb0470" ref-type="bibr">94</xref>], with an increase of IL-10 [<xref rid="bb0230" ref-type="bibr">46</xref>]. This support the notion of an anti-inflammatory effect of CP in subjects with acute viral infections.</p><p id="p0175">Cytotoxicity is also regulated by administration of IVIg. In the study of Klehmet et al. [<xref rid="bb0475" ref-type="bibr">95</xref>], authors found that patients with chronic inflammatory demyelinating polyneuropathy treated with IVIg, showed reduction in CD8<sup>+</sup> T cells with high levels of CD4<sup>+</sup> T effector memory and T central memory cells. In another study, IVIg proved to reduce the activation of CD8<sup>+</sup> T cells associated with a T-cell receptor blockade, thus reducing the interaction between effector and target cells [<xref rid="bb0480" ref-type="bibr">96</xref>]. In subjects with Kawasaki disease, a high proportion of CD8<sup>+</sup> was associated with resistance to IVIg, thus suggesting that these cells could be considered a predictive factor for IVIg response [<xref rid="bb0485" ref-type="bibr">97</xref>].</p><p id="p0180">Recent studies have shown that IVIg reduces the proliferation of Th17 cells, as well as decreases the production of IL-17A, IL-17F, IL-21, and CCL20 [<xref rid="bb0490" ref-type="bibr">98</xref>,<xref rid="bb0495" ref-type="bibr">99</xref>]. In other study, IVIg appeared to modulate the Th17/Treg ratio which is associated with recurrent pregnancy loss [<xref rid="bb0500" ref-type="bibr">100</xref>]. It is plausible that CP may act in a similar way in patients with COVID-19 [<xref rid="bb0140" ref-type="bibr">28</xref>,<xref rid="bb0145" ref-type="bibr">29</xref>] (<xref rid="f0005" ref-type="fig">Fig. 1</xref>C).</p></sec><sec id="s0055"><label>4.5</label><title>B cells</title><p id="p0185">B cells are critical in adaptive immunity <italic>via</italic> production of antibodies and cytokines. In patients with demyelinating polyneuropathy, administration of IVIg was associated with overexpression of Fc&#x003b3;RIIB receptors on B cells [<xref rid="bb0505" ref-type="bibr">101</xref>,<xref rid="bb0510" ref-type="bibr">102</xref>]. IVIg abrogated TLR-9-dependent B cell responses. This was associated with IVIg inhibitions of NF-&#x003ba;B signaling pathway, reduction of CD25 and CD40 expression, and reduction of IL-6 and IL-10 production by B cells. This process seems to be regulated by SH2 domain&#x02013;containing phosphatase 1 [<xref rid="bb0515" ref-type="bibr">103</xref>].</p><p id="p0190">Proliferation and survival of B cells is mediated by the B cell&#x02013;activating factor (BAFF). In the study conducted by Le Pottier et al. [<xref rid="bb0520" ref-type="bibr">104</xref>], authors found that IVIg contained NAbs for BAFF. This could explain the reduction in proliferation, as well as the increased rates of apoptosis of B cells. Regarding the latter process, it was found that anti-Fas (anti-CD95) antibodies, present in IVIg preparations, induced apoptosis in B cells [<xref rid="bb0525" ref-type="bibr">105</xref>].</p><p id="p0195">In DCs, downregulation of costimulatory molecules following administration of IVIg has been observed. This is similar to B cells which exhibited a reduction in antigen-presentation activity secondary to IgG internalization, in concordance with a reduced IL-2 production by T cells [<xref rid="bb0530" ref-type="bibr">106</xref>]. Moreover, IVIg administration modulates B-cell receptor (BCR) signaling. In the study of S&#x000e9;&#x000ef;t&#x000e9; et al. [<xref rid="bb0535" ref-type="bibr">107</xref>], authors found that interaction between BCR and CD22 resulted in a down-regulation of tyrosine phosphorylation of Lyn and the B-cell linker proteins which resulted in a sustained activation of Erk 1/2 and arrest of the cell cycle at the G/1 phase.</p><p id="p0200">These mechanisms may account for immunomodulation of the inflammatory response in COVID-19 secondary to CP administration. As showed above, recent reports suggest the production of antiphospholipid antibodies in patients with COVID-19 together with an antiphospholipid-like syndrome [<xref rid="bb0330" ref-type="bibr">66</xref>], and the regulation of this cascade could be critical to avoid deleterious outcomes in these group of patients (<italic>i.e.</italic>, thrombosis, disseminated intravascular coagulopathy).</p></sec><sec id="s0060"><label>4.6</label><title>Other immune cells</title><p id="p0205">The major immunological factor suspected to be associated with inflammation and lung damage in COVID-19 is the activation of macrophages. It has been suggested that patients with COVID-19 may suffer from a macrophage activation syndrome-like disease associated to innate immune migration to lung tissues [<xref rid="bb0140" ref-type="bibr">28</xref>]. In this context, the inhibition of this immunological pathway may help to control excessive cytokine production and prevent pulmonary damage (<italic>i.e.</italic>, fibrosis). This was recently supported by the study of Blanco-Melo et al. [<xref rid="bb0540" ref-type="bibr">108</xref>] who described an up regulation of chemokines for innate immune cells in ferrets as well as in patients with COVID-19. Interestingly, results suggest that this scenario mainly occurred in the first 7&#x000a0;days post infection, whereas at day 14th, other cytokines such as IL-6 and IL-1 persisted activated [<xref rid="bb0540" ref-type="bibr">108</xref>]. These data have critical therapeutic consequences.</p><p id="p0210">In the study conducted by Kozicky et al. [<xref rid="bb0545" ref-type="bibr">109</xref>], authors found that macrophages treated with IVIg showed an increased production of IL-10, with a reduction in IL-12/23p40, thus suggesting the promotion of an anti-inflammatory macrophage profile. Although there is no evidence of macrophage pulmonary migration inhibition by IVIg, a study on induced peripheral neurotoxicity showed that this treatment reduced nerve macrophage infiltration in rats [<xref rid="bb0550" ref-type="bibr">110</xref>]. These observations deserve attention in those patients treated with CP-COVID-19 since they may account for the positive results encountered in critically ill patients with COVID-19 [<xref rid="bb0190" ref-type="bibr">38</xref>,<xref rid="bb0195" ref-type="bibr">39</xref>]. In this line, we argue for CP-COVID-19 administration in early stages of diseases to prevent innate immune cells migration and avoid lung damage.</p></sec></sec><sec id="s0065"><label>5</label><title>Conclusions</title><p id="p0215">CP is a safe and potentially effective strategy for the treatment of emerging and re-emerging pathogens, especially in those scenarios without proved antiviral agents or vaccines. IVIg and CP shared similar mechanisms of action. The potential antiviral and immunomodulatory effects of CP are currently evaluated in COVID-19. According to the physiopathology of COVID-19 severe patients should be privileged over critical ones in order to reduce mortality and improve outcomes.</p></sec><sec id="s0070"><title>Funding</title><p id="p0220">This work was supported by <funding-source id="gts0005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100008793</institution-id><institution>Universidad del Rosario</institution></institution-wrap></funding-source> (ABN-011), Bogota, and <funding-source id="gts0010">Universidad CES (Office of Research and Innovation)</funding-source>, Medellin, Colombia.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>A.C.K.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name></person-group><article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title><source>Trends Microbiol</source><volume>24</volume><year>2016</year><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2016.03.003</pub-id><pub-id pub-id-type="pmid">27012512</pub-id></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Cavanagh</surname><given-names>D.</given-names></name></person-group><article-title>Coronavirus avian infectious bronchitis virus</article-title><source>Vet Res</source><volume>38</volume><year>2007</year><fpage>281</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1051/vetres:2006055</pub-id><pub-id pub-id-type="pmid">17296157</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Ismail</surname><given-names>M.M.</given-names></name><name><surname>Tang</surname><given-names>A.Y.</given-names></name><name><surname>Saif</surname><given-names>Y.M.</given-names></name></person-group><article-title>Pathogenicity of turkey coronavirus in turkeys and chickens</article-title><source>Avian Dis</source><volume>47</volume><year>2003</year><fpage>515</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1637/5917</pub-id><pub-id pub-id-type="pmid">14562877</pub-id></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>Q.-H.</given-names></name><name><surname>Luo</surname><given-names>X.-D.</given-names></name><name><surname>Hui</surname><given-names>W.-L.</given-names></name></person-group><article-title>Advances in clinical diagnosis and treatment of severe acute respiratory syndrome</article-title><source>World J Gastroenterol</source><volume>9</volume><year>2003</year><fpage>1139</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.3748/wjg.v9.i6.1139</pub-id><pub-id pub-id-type="pmid">12800213</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.M.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N Engl J Med</source><volume>367</volume><year>2012</year><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1211721</pub-id><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Phua</surname><given-names>J.</given-names></name><name><surname>Weng</surname><given-names>L.</given-names></name><name><surname>Ling</surname><given-names>L.</given-names></name><name><surname>Egi</surname><given-names>M.</given-names></name><name><surname>Lim</surname><given-names>C.-M.</given-names></name><name><surname>Divatia</surname><given-names>J.V.</given-names></name></person-group><article-title>Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations</article-title><source>Lancet Respir Med</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30161-2</pub-id></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N Engl J Med</source><volume>382</volume><year>2020</year><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.-W.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Kok</surname><given-names>K.-H.</given-names></name><name><surname>To</surname><given-names>K.K.-W.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>514</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30154-9</pub-id><pub-id pub-id-type="pmid">31986261</pub-id></element-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Shoenfeld</surname><given-names>Y.</given-names></name></person-group><article-title>Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning</article-title><source>Autoimmun Rev</source><volume>102538</volume><year>2020</year><pub-id pub-id-type="doi">10.1016/j.autrev.2020.102538</pub-id></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Kanduc</surname><given-names>D.</given-names></name><name><surname>Shoenfeld</surname><given-names>Y.</given-names></name></person-group><article-title>On the molecular determinants and the mechanism of the SARS-CoV-2 attack 2020</article-title><source>Clin Immunol</source><volume>215</volume><year>2020</year><fpage>108426</fpage><pub-id pub-id-type="doi">10.1016/j.clim.2020.108426</pub-id><pub-id pub-id-type="pmid">32311462</pub-id></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>M.</given-names></name><name><surname>Restrepo-Jim&#x000e9;nez</surname><given-names>P.</given-names></name><name><surname>Monsalve</surname><given-names>D.M.</given-names></name><name><surname>Pacheco</surname><given-names>Y.</given-names></name><name><surname>Acosta-Ampudia</surname><given-names>Y.</given-names></name><name><surname>Ram&#x000ed;rez-Santana</surname><given-names>C.</given-names></name></person-group><article-title>Molecular mimicry and autoimmunity</article-title><source>J Autoimmun</source><volume>95</volume><year>2018</year><fpage>100</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2018.10.012</pub-id><pub-id pub-id-type="pmid">30509385</pub-id></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name></person-group><article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Yan</surname><given-names>D.</given-names></name></person-group><article-title>Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial</article-title><source>MedRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.22.20040758</pub-id></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P.</given-names></name><name><surname>Lagier</surname><given-names>J.-C.</given-names></name><name><surname>Parola</surname><given-names>P.</given-names></name><name><surname>Hoang</surname><given-names>V.T.</given-names></name><name><surname>Meddeb</surname><given-names>L.</given-names></name><name><surname>Mailhe</surname><given-names>M.</given-names></name></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial</article-title><source>Int J Antimicrob Agents</source><volume>105949</volume><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Borba</surname><given-names>M.G.S.</given-names></name><name><surname>Val</surname><given-names>F.F.A.</given-names></name><name><surname>Sampaio</surname><given-names>V.S.</given-names></name><name><surname>Alexandre</surname><given-names>M.A.A.</given-names></name><name><surname>Melo</surname><given-names>G.C.</given-names></name><name><surname>Brito</surname><given-names>M.</given-names></name></person-group><article-title>Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial</article-title><source>JAMA Netw Open</source><volume>3</volume><year>2020</year><object-id pub-id-type="publisher-id">e208857</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.8857</pub-id></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Marano</surname><given-names>G.</given-names></name><name><surname>Vaglio</surname><given-names>S.</given-names></name><name><surname>Pupella</surname><given-names>S.</given-names></name><name><surname>Facco</surname><given-names>G.</given-names></name><name><surname>Catalano</surname><given-names>L.</given-names></name><name><surname>Liumbruno</surname><given-names>G.M.</given-names></name></person-group><article-title>Convalescent plasma: New evidence for an old therapeutic tool?</article-title><source>Blood Transfus</source><volume>14</volume><year>2016</year><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.2450/2015.0131-15</pub-id><pub-id pub-id-type="pmid">26674811</pub-id></element-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Burnouf</surname><given-names>T.</given-names></name><name><surname>Seghatchian</surname><given-names>J.</given-names></name></person-group><article-title>Ebola virus convalescent blood products: Where we are now and where we may need to go</article-title><source>Transfus Apher Sci</source><volume>51</volume><year>2014</year><fpage>120</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.transci.2014.10.003</pub-id><pub-id pub-id-type="pmid">25457751</pub-id></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Mair-Jenkins</surname><given-names>J.</given-names></name><name><surname>Saavedra-Campos</surname><given-names>M.</given-names></name><name><surname>Baillie</surname><given-names>J.K.</given-names></name><name><surname>Cleary</surname><given-names>P.</given-names></name><name><surname>Khaw</surname><given-names>F.-M.</given-names></name><name><surname>Lim</surname><given-names>W.S.</given-names></name></person-group><article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis</article-title><source>J Infect Dis</source><volume>211</volume><year>2015</year><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu396</pub-id><pub-id pub-id-type="pmid">25030060</pub-id></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>M.</given-names></name><name><surname>Monsalve</surname><given-names>D.M.</given-names></name><name><surname>Pacheco</surname><given-names>Y.</given-names></name><name><surname>Acosta-Ampudia</surname><given-names>Y.</given-names></name><name><surname>Ram&#x000ed;rez-Santana</surname><given-names>C.</given-names></name><name><surname>Ansari</surname><given-names>A.A.</given-names></name></person-group><article-title>Ebola virus disease: An emerging and re-emerging viral threat</article-title><source>J Autoimmun</source><volume>106</volume><year>2020</year><fpage>102375</fpage><pub-id pub-id-type="doi">10.1016/j.jaut.2019.102375</pub-id><pub-id pub-id-type="pmid">31806422</pub-id></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Planitzer</surname><given-names>C.B.</given-names></name><name><surname>Modrof</surname><given-names>J.</given-names></name><name><surname>Kreil</surname><given-names>T.R.</given-names></name></person-group><article-title>West Nile virus neutralization by US plasma-derived immunoglobulin products</article-title><source>J Infect Dis</source><volume>196</volume><year>2007</year><fpage>435</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1086/519392</pub-id><pub-id pub-id-type="pmid">17597458</pub-id></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Haley</surname><given-names>M.</given-names></name><name><surname>Retter</surname><given-names>A.S.</given-names></name><name><surname>Fowler</surname><given-names>D.</given-names></name><name><surname>Gea-Banacloche</surname><given-names>J.</given-names></name><name><surname>O&#x02019;Grady</surname><given-names>N.P.</given-names></name></person-group><article-title>The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis</article-title><source>Clin Infect Dis</source><volume>37</volume><year>2003</year><fpage>e88</fpage><lpage>e90</lpage><pub-id pub-id-type="doi">10.1086/377172</pub-id><pub-id pub-id-type="pmid">12955669</pub-id></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Shimoni</surname><given-names>Z.</given-names></name><name><surname>Niven</surname><given-names>M.J.</given-names></name><name><surname>Pitlick</surname><given-names>S.</given-names></name><name><surname>Bulvik</surname><given-names>S.</given-names></name></person-group><article-title>Treatment of West Nile virus encephalitis with intravenous immunoglobulin</article-title><source>Emerg Infect Dis</source><volume>7</volume><year>2001</year><fpage>759</fpage><pub-id pub-id-type="doi">10.3201/eid0704.010432</pub-id></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>van Griensven</surname><given-names>J.</given-names></name><name><surname>Edwards</surname><given-names>T.</given-names></name><name><surname>de Lamballerie</surname><given-names>X.</given-names></name><name><surname>Semple</surname><given-names>M.G.</given-names></name><name><surname>Gallian</surname><given-names>P.</given-names></name><name><surname>Baize</surname><given-names>S.</given-names></name></person-group><article-title>Evaluation of convalescent plasma for Ebola virus disease in Guinea</article-title><source>N Engl J Med</source><volume>374</volume><year>2016</year><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1511812</pub-id><pub-id pub-id-type="pmid">26735992</pub-id></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Garraud</surname><given-names>O.</given-names></name><name><surname>Heshmati</surname><given-names>F.</given-names></name><name><surname>Pozzetto</surname><given-names>B.</given-names></name><name><surname>Lefrere</surname><given-names>F.</given-names></name><name><surname>Girot</surname><given-names>R.</given-names></name><name><surname>Saillol</surname><given-names>A.</given-names></name></person-group><article-title>Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow</article-title><source>Transfus Clin Biol</source><volume>23</volume><year>2016</year><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.tracli.2015.12.003</pub-id><pub-id pub-id-type="pmid">26775794</pub-id></element-citation></ref><ref id="bb0135"><label>27</label><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>L&#x000fc;nemann</surname><given-names>J.D.</given-names></name><name><surname>Nimmerjahn</surname><given-names>F.</given-names></name><name><surname>Dalakas</surname><given-names>M.C.</given-names></name></person-group><article-title>Intravenous immunoglobulin in neurology--mode of action and clinical efficacy</article-title><source>Nat Rev Neurol</source><volume>11</volume><year>2015</year><fpage>80</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.253</pub-id><pub-id pub-id-type="pmid">25561275</pub-id></element-citation></ref><ref id="bb0140"><label>28</label><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>McGonagle</surname><given-names>D.</given-names></name><name><surname>Sharif</surname><given-names>K.</given-names></name><name><surname>O&#x02019;Regan</surname><given-names>A.</given-names></name><name><surname>Bridgewood</surname><given-names>C.</given-names></name></person-group><article-title>The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease</article-title><source>Autoimmun Rev</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.autrev.2020.102537</pub-id><comment>In press:102537</comment></element-citation></ref><ref id="bb0145"><label>29</label><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>S.</given-names></name><name><surname>Yi</surname><given-names>Q.</given-names></name><name><surname>Fan</surname><given-names>S.</given-names></name><name><surname>Lv</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name></person-group><article-title>Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)</article-title><source>MedRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.02.10.20021832</pub-id></element-citation></ref><ref id="bb0150"><label>30</label><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Shahani</surname><given-names>L.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Khardori</surname><given-names>N.M.</given-names></name></person-group><article-title>Immunotherapy in clinical medicine: Historical perspective and current status</article-title><source>Med Clin North Am</source><volume>96</volume><year>2012</year><fpage>421</fpage><lpage>431</lpage><comment>ix</comment><pub-id pub-id-type="doi">10.1016/j.mcna.2012.04.001</pub-id><pub-id pub-id-type="pmid">22703849</pub-id></element-citation></ref><ref id="bb0155"><label>31</label><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Shakir</surname><given-names>E.M.</given-names></name><name><surname>Cheung</surname><given-names>D.S.</given-names></name><name><surname>Grayson</surname><given-names>M.H.</given-names></name></person-group><article-title>Mechanisms of immunotherapy: A historical perspective</article-title><source>Ann Allergy Asthma Immunol</source><volume>105</volume><year>2010</year><fpage>340</fpage><lpage>347</lpage><comment>quiz 348, 368</comment><pub-id pub-id-type="doi">10.1016/j.anai.2010.09.012</pub-id><pub-id pub-id-type="pmid">21055659</pub-id></element-citation></ref><ref id="bb0160"><label>32</label><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name><surname>Sherer</surname><given-names>Y.</given-names></name><name><surname>Levy</surname><given-names>Y.</given-names></name><name><surname>Shoenfeld</surname><given-names>Y.</given-names></name></person-group><article-title>IVIG in autoimmunity and cancer--efficacy versus safety</article-title><source>Expert Opin Drug Saf</source><volume>1</volume><year>2002</year><fpage>153</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1517/14740338.1.2.153</pub-id><pub-id pub-id-type="pmid">12904149</pub-id></element-citation></ref><ref id="bb0165"><label>33</label><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>U.</given-names></name><name><surname>Achiron</surname><given-names>A.</given-names></name><name><surname>Sherer</surname><given-names>Y.</given-names></name><name><surname>Shoenfeld</surname><given-names>Y.</given-names></name></person-group><article-title>Safety of intravenous immunoglobulin (IVIG) therapy</article-title><source>Autoimmun Rev</source><volume>6</volume><year>2007</year><fpage>257</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2006.08.011</pub-id><pub-id pub-id-type="pmid">17317619</pub-id></element-citation></ref><ref id="bb0170"><label>34</label><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>J.Y.</given-names></name><name><surname>Sohn</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Cho</surname><given-names>Y.</given-names></name><name><surname>Hyun</surname><given-names>J.H.</given-names></name><name><surname>Baek</surname><given-names>Y.J.</given-names></name></person-group><article-title>Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea</article-title><source>J Korean Med Sci</source><volume>35</volume><year>2020</year><object-id pub-id-type="publisher-id">e149</object-id><pub-id pub-id-type="doi">10.3346/jkms.2020.35.e149</pub-id></element-citation></ref><ref id="bb0175"><label>35</label><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>J.-H.</given-names></name><name><surname>Seok</surname><given-names>H.</given-names></name><name><surname>Cho</surname><given-names>S.Y.</given-names></name><name><surname>Ha</surname><given-names>Y.E.</given-names></name><name><surname>Baek</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>S.H.</given-names></name></person-group><article-title>Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience</article-title><source>Antivir Ther</source><volume>23</volume><year>2018</year><fpage>617</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.3851/IMP3243</pub-id><pub-id pub-id-type="pmid">29923831</pub-id></element-citation></ref><ref id="bb0180"><label>36</label><element-citation publication-type="book" id="rf0180"><person-group person-group-type="author"><name><surname>Spalter</surname><given-names>S.H.</given-names></name><name><surname>Kaveri</surname><given-names>S.</given-names></name><name><surname>Kazatchkine</surname><given-names>M.D.</given-names></name></person-group><chapter-title>Anti-idiotypes to autoantibodies in therapeutic preparations of normal polyspecific human IgG (intravenous immunoglobulin, IVIg)</chapter-title><comment>editors</comment><person-group person-group-type="editor"><name><surname>Shoenfeld</surname><given-names>Y.</given-names></name><name><surname>Kennedy</surname><given-names>R.C.</given-names></name><name><surname>Ferrone Infection and Cancer SBT-I in MA</surname></name></person-group><source>Idiotypes Med. Autoimmun. Infect. Cancer</source><year>1997</year><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam</publisher-loc><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/B978-044482807-1/50021-1</pub-id></element-citation></ref><ref id="bb0185"><label>37</label><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>M.</given-names></name><name><surname>Fu</surname><given-names>D.</given-names></name><name><surname>Ren</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Treatment with convalescent plasma for COVID-19 patients in Wuhan, China</article-title><source>J Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25882</pub-id></element-citation></ref><ref id="bb0190"><label>38</label><element-citation publication-type="journal" id="rf0190"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name></person-group><article-title>Treatment of 5 critically ill patients with Covid-19 with convalescent plasma</article-title><source>JAMA</source><volume>323</volume><issue>16</issue><year>2020</year><fpage>1582</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.4783</pub-id></element-citation></ref><ref id="bb0195"><label>39</label><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name></person-group><article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><pub-id pub-id-type="doi">10.1073/pnas.2004168117</pub-id></element-citation></ref><ref id="bb0200"><label>40</label><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name><surname>Soo</surname><given-names>Y.O.Y.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>R.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Lee</surname><given-names>C.K.</given-names></name><name><surname>Tsang</surname><given-names>K.K.S.</given-names></name></person-group><article-title>Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients</article-title><source>Clin Microbiol Infect</source><volume>10</volume><year>2004</year><fpage>676</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2004.00956.x</pub-id><pub-id pub-id-type="pmid">15214887</pub-id></element-citation></ref><ref id="bb0205"><label>41</label><element-citation publication-type="journal" id="rf0205"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>R.</given-names></name><name><surname>Soo</surname><given-names>Y.O.Y.</given-names></name><name><surname>Wong</surname><given-names>W.S.</given-names></name><name><surname>Lee</surname><given-names>C.K.</given-names></name><name><surname>Ng</surname><given-names>M.H.L.</given-names></name></person-group><article-title>Use of convalescent plasma therapy in SARS patients in Hong Kong</article-title><source>Eur J Clin Microbiol Infect Dis</source><volume>24</volume><year>2005</year><fpage>44</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1007/s10096-004-1271-9</pub-id><pub-id pub-id-type="pmid">15616839</pub-id></element-citation></ref><ref id="bb0210"><label>42</label><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>K.-M.</given-names></name><name><surname>Chiueh</surname><given-names>T.-S.</given-names></name><name><surname>Siu</surname><given-names>L.K.</given-names></name><name><surname>Lin</surname><given-names>J.-C.</given-names></name><name><surname>Chan</surname><given-names>P.K.S.</given-names></name><name><surname>Peng</surname><given-names>M.-Y.</given-names></name></person-group><article-title>Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital</article-title><source>J Antimicrob Chemother</source><volume>56</volume><year>2005</year><fpage>919</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1093/jac/dki346</pub-id><pub-id pub-id-type="pmid">16183666</pub-id></element-citation></ref><ref id="bb0215"><label>43</label><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Jiang</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Nie</surname><given-names>W.</given-names></name></person-group><article-title>Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area</article-title><source>Zhonghua Yi Xue Za Zhi</source><volume>83</volume><year>2003</year><fpage>1018</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">12899773</pub-id></element-citation></ref><ref id="bb0220"><label>44</label><element-citation publication-type="journal" id="rf0220"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>L.</given-names></name></person-group><article-title>Letter to editor</article-title><source>Transfus Apher Sci</source><volume>29</volume><year>2003</year><fpage>101</fpage><pub-id pub-id-type="doi">10.1016/S1473-0502(03)00109-5</pub-id><pub-id pub-id-type="pmid">12952008</pub-id></element-citation></ref><ref id="bb0225"><label>45</label><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>V.W.S.</given-names></name><name><surname>Dai</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>A.K.L.</given-names></name><name><surname>Sung</surname><given-names>J.J.Y.</given-names></name></person-group><article-title>Treatment of severe acute respiratory syndrome with convalescent plasma</article-title><source>Hong Kong Med J</source><volume>9</volume><year>2003</year><fpage>199</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">12777656</pub-id></element-citation></ref><ref id="bb0230"><label>46</label><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>To KK</surname></name><name><surname>Lee</surname><given-names>C.-K.</given-names></name><name><surname>Lee</surname><given-names>K.-L.</given-names></name><name><surname>Chan</surname><given-names>K.</given-names></name><name><surname>Yan</surname><given-names>W.-W.</given-names></name></person-group><article-title>Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection</article-title><source>Clin Infect Dis</source><volume>52</volume><year>2011</year><fpage>447</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1093/cid/ciq106</pub-id><pub-id pub-id-type="pmid">21248066</pub-id></element-citation></ref><ref id="bb0235"><label>47</label><element-citation publication-type="journal" id="rf0235"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>K.K.C.</given-names></name><name><surname>Lee</surname><given-names>K.L.</given-names></name><name><surname>Lam</surname><given-names>P.K.N.</given-names></name><name><surname>Law</surname><given-names>K.I.</given-names></name><name><surname>Joynt</surname><given-names>G.M.</given-names></name><name><surname>Yan</surname><given-names>W.W.</given-names></name></person-group><article-title>Hong Kong&#x02019;s experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1)</article-title><source>Hong Kong Med J</source><volume>16</volume><year>2010</year><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">21135421</pub-id></element-citation></ref><ref id="bb0240"><label>48</label><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Shu</surname><given-names>Y.</given-names></name><name><surname>Xiang</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name></person-group><article-title>Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China</article-title><source>PLoS One</source><volume>3</volume><year>2008</year><object-id pub-id-type="publisher-id">e2985</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002985</pub-id></element-citation></ref><ref id="bb0245"><label>49</label><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>L.K.</given-names></name><name><surname>Zhou</surname><given-names>B.P.</given-names></name></person-group><article-title>Successful treatment of avian influenza with convalescent plasma</article-title><source>Hong Kong Med J</source><volume>12</volume><year>2006</year><fpage>489</fpage></element-citation></ref><ref id="bb0250"><label>50</label><element-citation publication-type="journal" id="rf0250"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>S.S.Y.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group><article-title>The management of coronavirus infections with particular reference to SARS</article-title><source>J Antimicrob Chemother</source><volume>62</volume><year>2008</year><fpage>437</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn243</pub-id><pub-id pub-id-type="pmid">18565970</pub-id></element-citation></ref><ref id="bb0255"><label>51</label><element-citation publication-type="journal" id="rf0255"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zeng</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>Clinical characteristics and therapeutic experience of case of severe highly pathogenic A/H5N1 avian influenza with bronchopleural fistula</article-title><source>Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese J Tuberc Respir Dis</source><volume>32</volume><year>2009</year><fpage>356</fpage><lpage>359</lpage></element-citation></ref><ref id="bb0260"><label>52</label><element-citation publication-type="journal" id="rf0260"><person-group person-group-type="author"><name><surname>Tiberghien</surname><given-names>P.</given-names></name><name><surname>de Lambalerie</surname><given-names>X.</given-names></name><name><surname>Morel</surname><given-names>P.</given-names></name><name><surname>Gallian</surname><given-names>P.</given-names></name><name><surname>Lacombe</surname><given-names>K.</given-names></name><name><surname>Yazdanpanah</surname><given-names>Y.</given-names></name></person-group><article-title>Collecting and evaluating convalescent plasma for COVID-19 treatment: Why and how</article-title><source>Vox Sang</source><year>2020</year><pub-id pub-id-type="doi">10.1111/vox.12926</pub-id></element-citation></ref><ref id="bb0265"><label>53</label><element-citation publication-type="journal" id="rf0265"><person-group person-group-type="author"><name><surname>Tissot</surname><given-names>J.-D.</given-names></name><name><surname>Garraud</surname><given-names>O.</given-names></name></person-group><article-title>Ethics and blood donation: A marriage of convenience</article-title><source>Press Medicale</source><volume>45</volume><year>2016</year><fpage>e247</fpage><lpage>e252</lpage><pub-id pub-id-type="doi">10.1016/j.lpm.2016.06.016</pub-id></element-citation></ref><ref id="bb0270"><label>54</label><element-citation publication-type="journal" id="rf0270"><person-group person-group-type="author"><name><surname>Bloch</surname><given-names>E.M.</given-names></name><name><surname>Shoham</surname><given-names>S.</given-names></name><name><surname>Casadevall</surname><given-names>A.</given-names></name><name><surname>Sachais</surname><given-names>B.S.</given-names></name><name><surname>Shaz</surname><given-names>B.</given-names></name><name><surname>Winters</surname><given-names>J.L.</given-names></name></person-group><article-title>Deployment of convalescent plasma for the prevention and treatment of COVID-19</article-title><source>J Clin Invest</source><year>2020</year><pub-id pub-id-type="doi">10.1172/JCI138745</pub-id></element-citation></ref><ref id="bb0275"><label>55</label><element-citation publication-type="journal" id="rf0275"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>R.Y.</given-names></name><name><surname>Crowder</surname><given-names>L.A.</given-names></name><name><surname>Haynes</surname><given-names>J.M.</given-names></name><name><surname>Notari</surname><given-names>E.P.</given-names></name><name><surname>Stramer</surname><given-names>S.L.</given-names></name><name><surname>Steele</surname><given-names>W.R.</given-names></name></person-group><article-title>Screening blood donors for HIV, HCV, and HBV at the American Red Cross: 10-year trends in prevalence, incidence, and residual risk, 2007 to 2016</article-title><source>Transfus Med Rev</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.tmrv.2020.02.001</pub-id></element-citation></ref><ref id="bb0280"><label>56</label><element-citation publication-type="journal" id="rf0280"><person-group person-group-type="author"><name><surname>Niazi</surname><given-names>S.K.</given-names></name><name><surname>Bhatti</surname><given-names>F.A.</given-names></name><name><surname>Salamat</surname><given-names>N.</given-names></name><name><surname>Ghani</surname><given-names>E.</given-names></name><name><surname>Tayyab</surname><given-names>M.</given-names></name></person-group><article-title>Impact of nucleic acid amplification test on screening of blood donors in Northern Pakistan</article-title><source>Transfusion</source><volume>55</volume><year>2015</year><fpage>1803</fpage><lpage>1811</lpage><pub-id pub-id-type="doi">10.1111/trf.13017</pub-id><pub-id pub-id-type="pmid">25648663</pub-id></element-citation></ref><ref id="bb0285"><label>57</label><element-citation publication-type="journal" id="rf0285"><person-group person-group-type="author"><name><surname>Bello-L&#x000f3;pez</surname><given-names>J.M.</given-names></name><name><surname>Delgado-Balbuena</surname><given-names>L.</given-names></name><name><surname>Rojas-Huidobro</surname><given-names>D.</given-names></name><name><surname>Rojo-Medina</surname><given-names>J.</given-names></name></person-group><article-title>Treatment of platelet concentrates and plasma with riboflavin and UV light: Impact in bacterial reduction</article-title><source>Transfus Clin Biol</source><volume>25</volume><year>2018</year><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.tracli.2018.03.004</pub-id><pub-id pub-id-type="pmid">29656962</pub-id></element-citation></ref><ref id="bb0290"><label>58</label><element-citation publication-type="journal" id="rf0290"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>R.J.</given-names></name><name><surname>McLaughlin</surname><given-names>L.S.</given-names></name></person-group><article-title>Plasma components: Properties, differences, and uses</article-title><source>Transfusion</source><volume>52</volume><issue>Suppl. 1</issue><year>2012</year><fpage>9S</fpage><lpage>19S</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2012.03622.x</pub-id><pub-id pub-id-type="pmid">22578375</pub-id></element-citation></ref><ref id="bb0295"><label>59</label><element-citation publication-type="journal" id="rf0295"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>B.-J.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>The spike protein of SARS-CoV--a target for vaccine and therapeutic development</article-title><source>Nat Rev Microbiol</source><volume>7</volume><year>2009</year><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2090</pub-id><pub-id pub-id-type="pmid">19198616</pub-id></element-citation></ref><ref id="bb0300"><label>60</label><element-citation publication-type="journal" id="rf0300"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>A.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name></person-group><article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</article-title><source>Emerg Microbes Infect</source><volume>9</volume><year>2020</year><fpage>382</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1729069</pub-id><pub-id pub-id-type="pmid">32065055</pub-id></element-citation></ref><ref id="bb0305"><label>61</label><element-citation publication-type="journal" id="rf0305"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name></person-group><article-title>Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications</article-title><source>MedRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.30.20047365</pub-id></element-citation></ref><ref id="bb0310"><label>62</label><element-citation publication-type="journal" id="rf0310"><person-group person-group-type="author"><name><surname>Hsueh</surname><given-names>P.-R.</given-names></name><name><surname>Huang</surname><given-names>L.-M.</given-names></name><name><surname>Chen</surname><given-names>P.-J.</given-names></name><name><surname>Kao</surname><given-names>C.-L.</given-names></name><name><surname>Yang</surname><given-names>P.-C.</given-names></name></person-group><article-title>Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus</article-title><source>Clin Microbiol Infect</source><volume>10</volume><year>2004</year><fpage>1062</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2004.01009.x</pub-id><pub-id pub-id-type="pmid">15606632</pub-id></element-citation></ref><ref id="bb0315"><label>63</label><element-citation publication-type="journal" id="rf0315"><person-group person-group-type="author"><name><surname>Gorse</surname><given-names>G.J.</given-names></name><name><surname>Donovan</surname><given-names>M.M.</given-names></name><name><surname>Patel</surname><given-names>G.B.</given-names></name></person-group><article-title>Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses</article-title><source>J Med Virol</source><volume>92</volume><year>2020</year><fpage>512</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1002/jmv.25715</pub-id><pub-id pub-id-type="pmid">32073157</pub-id></element-citation></ref><ref id="bb0320"><label>64</label><element-citation publication-type="journal" id="rf0320"><person-group person-group-type="author"><name><surname>Rokni</surname><given-names>M.</given-names></name><name><surname>Ghasemi</surname><given-names>V.</given-names></name><name><surname>Tavakoli</surname><given-names>Z.</given-names></name></person-group><article-title>Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS</article-title><source>Rev Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/rmv.2107</pub-id></element-citation></ref><ref id="bb0325"><label>65</label><element-citation publication-type="journal" id="rf0325"><person-group person-group-type="author"><name><surname>Chaigne</surname><given-names>B.</given-names></name><name><surname>Mouthon</surname><given-names>L.</given-names></name></person-group><article-title>Mechanisms of action of intravenous immunoglobulin</article-title><source>Transfus Apher Sci</source><volume>56</volume><year>2017</year><fpage>45</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.transci.2016.12.017</pub-id><pub-id pub-id-type="pmid">28161150</pub-id></element-citation></ref><ref id="bb0330"><label>66</label><element-citation publication-type="journal" id="rf0330"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Xia</surname><given-names>P.</given-names></name><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name></person-group><article-title>Coagulopathy and antiphospholipid antibodies in patients with Covid-19</article-title><source>N Engl J Med</source><volume>382</volume><issue>17</issue><year>2020</year><fpage>e38</fpage><pub-id pub-id-type="doi">10.1056/NEJMc2007575</pub-id><comment>In press</comment><pub-id pub-id-type="pmid">32268022</pub-id></element-citation></ref><ref id="bb0335"><label>67</label><element-citation publication-type="journal" id="rf0335"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>H.U.</given-names></name><name><surname>Sp&#x000e4;th</surname><given-names>P.J.</given-names></name></person-group><article-title>Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation</article-title><source>Clin Rev Allergy Immunol</source><volume>29</volume><year>2005</year><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1385/CRIAI:29:3:207</pub-id><pub-id pub-id-type="pmid">16391395</pub-id></element-citation></ref><ref id="bb0340"><label>68</label><element-citation publication-type="journal" id="rf0340"><person-group person-group-type="author"><name><surname>Basta</surname><given-names>M.</given-names></name><name><surname>Van Goor</surname><given-names>F.</given-names></name><name><surname>Luccioli</surname><given-names>S.</given-names></name><name><surname>Billings</surname><given-names>E.M.</given-names></name><name><surname>Vortmeyer</surname><given-names>A.O.</given-names></name><name><surname>Baranyi</surname><given-names>L.</given-names></name></person-group><article-title>F(ab)&#x02019;2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins</article-title><source>Nat Med</source><volume>9</volume><year>2003</year><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/nm836</pub-id><pub-id pub-id-type="pmid">12612546</pub-id></element-citation></ref><ref id="bb0345"><label>69</label><element-citation publication-type="journal" id="rf0345"><person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>L.E.</given-names></name><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Morrison</surname><given-names>T.E.</given-names></name><name><surname>Menachery</surname><given-names>V.D.</given-names></name><name><surname>Jensen</surname><given-names>K.</given-names></name><name><surname>Leist</surname><given-names>S.R.</given-names></name></person-group><article-title>Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis</article-title><source>MBio</source><volume>9</volume><year>2018</year><pub-id pub-id-type="doi">10.1128/mBio.01753-18</pub-id></element-citation></ref><ref id="bb0350"><label>70</label><element-citation publication-type="journal" id="rf0350"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>Y.</given-names></name><name><surname>Horiuchi</surname><given-names>A.</given-names></name><name><surname>Miyake</surname><given-names>M.</given-names></name><name><surname>Kimura</surname><given-names>S.</given-names></name></person-group><article-title>Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy</article-title><source>Immunol Rev</source><volume>139</volume><year>1994</year><fpage>5</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065x.1994.tb00854.x</pub-id><pub-id pub-id-type="pmid">7927413</pub-id></element-citation></ref><ref id="bb0355"><label>71</label><element-citation publication-type="book" id="rf0355"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>R.</given-names></name></person-group><chapter-title>Antibody-dependent enhancement of viral infections BT - Dynamics of immune activation in viral diseases</chapter-title><comment>editor</comment><person-group person-group-type="editor"><name><surname>Bramhachari</surname><given-names>P.V.</given-names></name></person-group><source>Dyn. Immune Act. Viral Dis</source><year>2020</year><publisher-name>Springer Singapore</publisher-name><publisher-loc>Singapore</publisher-loc><fpage>9</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/978-981-15-1045-8_2</pub-id></element-citation></ref><ref id="bb0360"><label>72</label><element-citation publication-type="journal" id="rf0360"><person-group person-group-type="author"><name><surname>Vatti</surname><given-names>A.</given-names></name><name><surname>Monsalve</surname><given-names>D.M.</given-names></name><name><surname>Pacheco</surname><given-names>Y.</given-names></name><name><surname>Chang</surname><given-names>C.</given-names></name><name><surname>Anaya</surname><given-names>J.-M.</given-names></name><name><surname>Gershwin</surname><given-names>M.E.</given-names></name></person-group><article-title>Original antigenic sin: A comprehensive review</article-title><source>J Autoimmun</source><volume>83</volume><year>2017</year><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2017.04.008</pub-id><pub-id pub-id-type="pmid">28479213</pub-id></element-citation></ref><ref id="bb0365"><label>73</label><element-citation publication-type="journal" id="rf0365"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.-F.</given-names></name><name><surname>Tseng</surname><given-names>S.-P.</given-names></name><name><surname>Yen</surname><given-names>C.-H.</given-names></name><name><surname>Yang</surname><given-names>J.-Y.</given-names></name><name><surname>Tsao</surname><given-names>C.-H.</given-names></name><name><surname>Shen</surname><given-names>C.-W.</given-names></name></person-group><article-title>Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins</article-title><source>Biochem Biophys Res Commun</source><volume>451</volume><year>2014</year><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.07.090</pub-id><pub-id pub-id-type="pmid">25073113</pub-id></element-citation></ref><ref id="bb0370"><label>74</label><element-citation publication-type="journal" id="rf0370"><person-group person-group-type="author"><name><surname>Casadevall</surname><given-names>A.</given-names></name><name><surname>Pirofski</surname><given-names>L.</given-names></name></person-group><article-title>The convalescent sera option for containing COVID-19</article-title><source>J Clin Invest</source><volume>130</volume><year>2020</year><fpage>1545</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1172/JCI138003</pub-id><pub-id pub-id-type="pmid">32167489</pub-id></element-citation></ref><ref id="bb0375"><label>75</label><element-citation publication-type="journal" id="rf0375"><person-group person-group-type="author"><name><surname>Nimmerjahn</surname><given-names>F.</given-names></name><name><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>Anti-inflammatory actions of intravenous immunoglobulin</article-title><source>Annu Rev Immunol</source><volume>26</volume><year>2008</year><fpage>513</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090232</pub-id><pub-id pub-id-type="pmid">18370923</pub-id></element-citation></ref><ref id="bb0380"><label>76</label><element-citation publication-type="journal" id="rf0380"><person-group person-group-type="author"><name><surname>Kiessling</surname><given-names>P.</given-names></name><name><surname>Lledo-Garcia</surname><given-names>R.</given-names></name><name><surname>Watanabe</surname><given-names>S.</given-names></name><name><surname>Langdon</surname><given-names>G.</given-names></name><name><surname>Tran</surname><given-names>D.</given-names></name><name><surname>Bari</surname><given-names>M.</given-names></name></person-group><article-title>The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study</article-title><source>Sci Transl Med</source><volume>9</volume><year>2017</year><pub-id pub-id-type="doi">10.1126/scitranslmed.aan1208</pub-id></element-citation></ref><ref id="bb0385"><label>77</label><element-citation publication-type="journal" id="rf0385"><person-group person-group-type="author"><name><surname>Litzman</surname><given-names>J.</given-names></name></person-group><article-title>Influence of FCRN expression on lung decline and intravenous immunoglobulin catabolism in common variable immunodeficiency patients</article-title><source>Clin Exp Immunol</source><volume>178</volume><issue>Suppl</issue><year>2014</year><fpage>103</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1111/cei.12529</pub-id><pub-id pub-id-type="pmid">25546780</pub-id></element-citation></ref><ref id="bb0390"><label>78</label><element-citation publication-type="journal" id="rf0390"><person-group person-group-type="author"><name><surname>Akilesh</surname><given-names>S.</given-names></name><name><surname>Petkova</surname><given-names>S.</given-names></name><name><surname>Sproule</surname><given-names>T.J.</given-names></name><name><surname>Shaffer</surname><given-names>D.J.</given-names></name><name><surname>Christianson</surname><given-names>G.J.</given-names></name><name><surname>Roopenian</surname><given-names>D.</given-names></name></person-group><article-title>The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease</article-title><source>J Clin Invest</source><volume>113</volume><year>2004</year><fpage>1328</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1172/JCI18838</pub-id><pub-id pub-id-type="pmid">15124024</pub-id></element-citation></ref><ref id="bb0395"><label>79</label><element-citation publication-type="journal" id="rf0395"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>R.J.</given-names></name><name><surname>Balthasar</surname><given-names>J.P.</given-names></name></person-group><article-title>Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia</article-title><source>Blood</source><volume>100</volume><year>2002</year><fpage>2087</fpage><lpage>2093</lpage><pub-id pub-id-type="pmid">12200371</pub-id></element-citation></ref><ref id="bb0400"><label>80</label><element-citation publication-type="journal" id="rf0400"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>R.J.</given-names></name><name><surname>Balthasar</surname><given-names>J.P.</given-names></name></person-group><article-title>Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor</article-title><source>Thromb Haemost</source><volume>88</volume><year>2002</year><fpage>898</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">12529736</pub-id></element-citation></ref><ref id="bb0405"><label>81</label><element-citation publication-type="journal" id="rf0405"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name></person-group><article-title>Fc&#x003b3;RIIb expression on B cells is associated with treatment efficacy for acute rejection after kidney transplantation</article-title><source>Mol Immunol</source><volume>85</volume><year>2017</year><fpage>283</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2017.03.006</pub-id><pub-id pub-id-type="pmid">28360016</pub-id></element-citation></ref><ref id="bb0410"><label>82</label><element-citation publication-type="journal" id="rf0410"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>S.</given-names></name><name><surname>Wiener</surname><given-names>H.</given-names></name><name><surname>Shendre</surname><given-names>A.</given-names></name><name><surname>Kaslow</surname><given-names>R.A.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Olson</surname><given-names>A.</given-names></name></person-group><article-title>Role of activating Fc&#x003b3;R gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response</article-title><source>Circ Cardiovasc Genet</source><volume>5</volume><year>2012</year><fpage>309</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.111.962464</pub-id><pub-id pub-id-type="pmid">22565545</pub-id></element-citation></ref><ref id="bb0415"><label>83</label><element-citation publication-type="journal" id="rf0415"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>Y.</given-names></name><name><surname>Nimmerjahn</surname><given-names>F.</given-names></name><name><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation</article-title><source>Science</source><volume>313</volume><issue>80</issue><year>2006</year><fpage>670</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1126/science.1129594</pub-id><pub-id pub-id-type="pmid">16888140</pub-id></element-citation></ref><ref id="bb0420"><label>84</label><element-citation publication-type="journal" id="rf0420"><person-group person-group-type="author"><name><surname>Othy</surname><given-names>S.</given-names></name><name><surname>Topcu</surname><given-names>S.</given-names></name><name><surname>Saha</surname><given-names>C.</given-names></name><name><surname>Kothapalli</surname><given-names>P.</given-names></name><name><surname>Lacroix-Desmazes</surname><given-names>S.</given-names></name><name><surname>Kasermann</surname><given-names>F.</given-names></name></person-group><article-title>Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin</article-title><source>Eur J Immunol</source><volume>44</volume><year>2014</year><fpage>2059</fpage><lpage>2063</lpage><pub-id pub-id-type="doi">10.1002/eji.201444440</pub-id><pub-id pub-id-type="pmid">24700174</pub-id></element-citation></ref><ref id="bb0425"><label>85</label><element-citation publication-type="journal" id="rf0425"><person-group person-group-type="author"><name><surname>Bayry</surname><given-names>J.</given-names></name><name><surname>Lacroix-Desmazes</surname><given-names>S.</given-names></name><name><surname>Carbonneil</surname><given-names>C.</given-names></name><name><surname>Misra</surname><given-names>N.</given-names></name><name><surname>Donkova</surname><given-names>V.</given-names></name><name><surname>Pashov</surname><given-names>A.</given-names></name></person-group><article-title>Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin</article-title><source>Blood</source><volume>101</volume><year>2003</year><fpage>758</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-05-1447</pub-id><pub-id pub-id-type="pmid">12393386</pub-id></element-citation></ref><ref id="bb0430"><label>86</label><element-citation publication-type="journal" id="rf0430"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Schoindre</surname><given-names>Y.</given-names></name><name><surname>Hegde</surname><given-names>P.</given-names></name><name><surname>Saha</surname><given-names>C.</given-names></name><name><surname>Maddur</surname><given-names>M.S.</given-names></name><name><surname>Stephen-Victor</surname><given-names>E.</given-names></name></person-group><article-title>Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients</article-title><source>Sci Rep</source><volume>4</volume><year>2014</year><fpage>5672</fpage><pub-id pub-id-type="doi">10.1038/srep05672</pub-id><pub-id pub-id-type="pmid">25012067</pub-id></element-citation></ref><ref id="bb0435"><label>87</label><element-citation publication-type="journal" id="rf0435"><person-group person-group-type="author"><name><surname>Tjon</surname><given-names>A.S.W.</given-names></name><name><surname>van Gent</surname><given-names>R.</given-names></name><name><surname>Jaadar</surname><given-names>H.</given-names></name><name><surname>Martin van Hagen</surname><given-names>P.</given-names></name><name><surname>Mancham</surname><given-names>S.</given-names></name><name><surname>van der Laan</surname><given-names>L.J.W.</given-names></name></person-group><article-title>Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production</article-title><source>J Immunol</source><volume>192</volume><year>2014</year><fpage>5625</fpage><lpage>5634</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301260</pub-id><pub-id pub-id-type="pmid">24808368</pub-id></element-citation></ref><ref id="bb0440"><label>88</label><element-citation publication-type="journal" id="rf0440"><person-group person-group-type="author"><name><surname>Karnam</surname><given-names>A.</given-names></name><name><surname>Rambabu</surname><given-names>N.</given-names></name><name><surname>Das</surname><given-names>M.</given-names></name><name><surname>Bou-Jaoudeh</surname><given-names>M.</given-names></name><name><surname>Delignat</surname><given-names>S.</given-names></name><name><surname>K&#x000e4;sermann</surname><given-names>F.</given-names></name></person-group><article-title>Therapeutic normal IgG intravenous immunoglobulin activates Wnt-&#x003b2;-catenin pathway in dendritic cells</article-title><source>Commun Biol</source><volume>3</volume><year>2020</year><fpage>96</fpage><pub-id pub-id-type="doi">10.1038/s42003-020-0825-4</pub-id><pub-id pub-id-type="pmid">32132640</pub-id></element-citation></ref><ref id="bb0445"><label>89</label><element-citation publication-type="journal" id="rf0445"><person-group person-group-type="author"><name><surname>Bayry</surname><given-names>J.</given-names></name><name><surname>Lacroix-Desmazes</surname><given-names>S.</given-names></name><name><surname>Delignat</surname><given-names>S.</given-names></name><name><surname>Mouthon</surname><given-names>L.</given-names></name><name><surname>Weill</surname><given-names>B.</given-names></name><name><surname>Kazatchkine</surname><given-names>M.D.</given-names></name></person-group><article-title>Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus</article-title><source>Arthritis Rheum</source><volume>48</volume><year>2003</year><fpage>3497</fpage><lpage>3502</lpage><pub-id pub-id-type="doi">10.1002/art.11346</pub-id><pub-id pub-id-type="pmid">14674000</pub-id></element-citation></ref><ref id="bb0450"><label>90</label><element-citation publication-type="journal" id="rf0450"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Saha</surname><given-names>C.</given-names></name><name><surname>Schoindre</surname><given-names>Y.</given-names></name><name><surname>Gilardin</surname><given-names>L.</given-names></name><name><surname>Benveniste</surname><given-names>O.</given-names></name><name><surname>Kaveri</surname><given-names>S.V.</given-names></name></person-group><article-title>Interferon-&#x003b1; inhibition by intravenous immunoglobulin is independent of modulation of the plasmacytoid dendritic cell population in the circulation: Comment on the article by Wiedeman et al</article-title><source>Arthritis Rheumatol</source><volume>66</volume><year>2014</year><fpage>2308</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.1002/art.38683</pub-id><pub-id pub-id-type="pmid">24782250</pub-id></element-citation></ref><ref id="bb0455"><label>91</label><element-citation publication-type="journal" id="rf0455"><person-group person-group-type="author"><name><surname>Aubin</surname><given-names>E.</given-names></name><name><surname>Lemieux</surname><given-names>R.</given-names></name><name><surname>Bazin</surname><given-names>R.</given-names></name></person-group><article-title>Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation</article-title><source>Blood</source><volume>115</volume><year>2010</year><fpage>1727</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-06-225417</pub-id><pub-id pub-id-type="pmid">19965673</pub-id></element-citation></ref><ref id="bb0460"><label>92</label><element-citation publication-type="journal" id="rf0460"><person-group person-group-type="author"><name><surname>Issekutz</surname><given-names>A.C.</given-names></name><name><surname>Rowter</surname><given-names>D.</given-names></name><name><surname>Miescher</surname><given-names>S.</given-names></name><name><surname>K&#x000e4;sermann</surname><given-names>F.</given-names></name></person-group><article-title>Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells</article-title><source>Clin Immunol</source><volume>160</volume><year>2015</year><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2015.05.003</pub-id><pub-id pub-id-type="pmid">25982320</pub-id></element-citation></ref><ref id="bb0465"><label>93</label><element-citation publication-type="journal" id="rf0465"><person-group person-group-type="author"><name><surname>Ahmadi</surname><given-names>M.</given-names></name><name><surname>Abdolmohammadi-Vahid</surname><given-names>S.</given-names></name><name><surname>Ghaebi</surname><given-names>M.</given-names></name><name><surname>Aghebati-Maleki</surname><given-names>L.</given-names></name><name><surname>Afkham</surname><given-names>A.</given-names></name><name><surname>Danaii</surname><given-names>S.</given-names></name></person-group><article-title>Effect of intravenous immunoglobulin on Th1 and Th2 lymphocytes and improvement of pregnancy outcome in recurrent pregnancy loss (RPL)</article-title><source>Biomed Pharmacother</source><volume>92</volume><year>2017</year><fpage>1095</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.06.001</pub-id><pub-id pub-id-type="pmid">28622710</pub-id></element-citation></ref><ref id="bb0470"><label>94</label><element-citation publication-type="journal" id="rf0470"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>I.F.N.</given-names></name><name><surname>KKW</surname><given-names>To</given-names></name><name><surname>Lee</surname><given-names>C.-K.</given-names></name><name><surname>Lee</surname><given-names>K.-L.</given-names></name><name><surname>Yan</surname><given-names>W.-W.</given-names></name><name><surname>Chan</surname><given-names>K.</given-names></name></person-group><article-title>Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection</article-title><source>Chest</source><volume>144</volume><year>2013</year><fpage>464</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1378/chest.12-2907</pub-id><pub-id pub-id-type="pmid">23450336</pub-id></element-citation></ref><ref id="bb0475"><label>95</label><element-citation publication-type="journal" id="rf0475"><person-group person-group-type="author"><name><surname>Klehmet</surname><given-names>J.</given-names></name><name><surname>Goehler</surname><given-names>J.</given-names></name><name><surname>Ulm</surname><given-names>L.</given-names></name><name><surname>Kohler</surname><given-names>S.</given-names></name><name><surname>Meisel</surname><given-names>C.</given-names></name><name><surname>Meisel</surname><given-names>A.</given-names></name></person-group><article-title>Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>86</volume><year>2015</year><fpage>686</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2014-307708</pub-id><pub-id pub-id-type="pmid">25074566</pub-id></element-citation></ref><ref id="bb0480"><label>96</label><element-citation publication-type="journal" id="rf0480"><person-group person-group-type="author"><name><surname>Tr&#x000e9;panier</surname><given-names>P.</given-names></name><name><surname>Chabot</surname><given-names>D.</given-names></name><name><surname>Bazin</surname><given-names>R.</given-names></name></person-group><article-title>Intravenous immunoglobulin modulates the expansion and cytotoxicity of CD8+ T cells</article-title><source>Immunology</source><volume>141</volume><year>2014</year><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1111/imm.12189</pub-id><pub-id pub-id-type="pmid">24128001</pub-id></element-citation></ref><ref id="bb0485"><label>97</label><element-citation publication-type="journal" id="rf0485"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q.</given-names></name><name><surname>Gong</surname><given-names>F.-Q.</given-names></name><name><surname>Shang</surname><given-names>S.-Q.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name></person-group><article-title>Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease</article-title><source>Clin Immunol</source><volume>171</volume><year>2016</year><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2016.08.012</pub-id><pub-id pub-id-type="pmid">27519954</pub-id></element-citation></ref><ref id="bb0490"><label>98</label><element-citation publication-type="journal" id="rf0490"><person-group person-group-type="author"><name><surname>Maddur</surname><given-names>M.S.</given-names></name><name><surname>Vani</surname><given-names>J.</given-names></name><name><surname>Hegde</surname><given-names>P.</given-names></name><name><surname>Lacroix-Desmazes</surname><given-names>S.</given-names></name><name><surname>Kaveri</surname><given-names>S.V.</given-names></name><name><surname>Bayry</surname><given-names>J.</given-names></name></person-group><article-title>Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin</article-title><source>J Allergy Clin Immunol</source><volume>127</volume><year>2011</year><fpage>823</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2010.12.1102</pub-id><pub-id pub-id-type="pmid">21281961</pub-id></element-citation></ref><ref id="bb0495"><label>99</label><element-citation publication-type="journal" id="rf0495"><person-group person-group-type="author"><name><surname>Maddur</surname><given-names>M.S.</given-names></name><name><surname>Kaveri</surname><given-names>S.V.</given-names></name><name><surname>Bayry</surname><given-names>J.</given-names></name></person-group><article-title>Comparison of different IVIg preparations on IL-17 production by human Th17 cells</article-title><source>Autoimmun Rev</source><volume>10</volume><year>2011</year><fpage>809</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2011.02.007</pub-id><pub-id pub-id-type="pmid">21376142</pub-id></element-citation></ref><ref id="bb0500"><label>100</label><element-citation publication-type="journal" id="rf0500"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.J.</given-names></name><name><surname>Lee</surname><given-names>S.K.</given-names></name><name><surname>Kim</surname><given-names>J.Y.</given-names></name><name><surname>Na</surname><given-names>B.J.</given-names></name><name><surname>Hur</surname><given-names>S.E.</given-names></name><name><surname>Lee</surname><given-names>M.</given-names></name></person-group><article-title>Intravenous immunoglobulin G modulates peripheral blood Th17 and Foxp3(+) regulatory T cells in pregnant women with recurrent pregnancy loss</article-title><source>Am J Reprod Immunol</source><volume>71</volume><year>2014</year><fpage>441</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1111/aji.12208</pub-id><pub-id pub-id-type="pmid">24645850</pub-id></element-citation></ref><ref id="bb0505"><label>101</label><element-citation publication-type="journal" id="rf0505"><person-group person-group-type="author"><name><surname>Tackenberg</surname><given-names>B.</given-names></name><name><surname>Jelcic</surname><given-names>I.</given-names></name><name><surname>Baerenwaldt</surname><given-names>A.</given-names></name><name><surname>Oertel</surname><given-names>W.H.</given-names></name><name><surname>Sommer</surname><given-names>N.</given-names></name><name><surname>Nimmerjahn</surname><given-names>F.</given-names></name></person-group><article-title>Impaired inhibitory Fc gamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy</article-title><source>Proc Natl Acad Sci U S A</source><volume>106</volume><year>2009</year><fpage>4788</fpage><lpage>4792</lpage><pub-id pub-id-type="doi">10.1073/pnas.0807319106</pub-id><pub-id pub-id-type="pmid">19261857</pub-id></element-citation></ref><ref id="bb0510"><label>102</label><element-citation publication-type="journal" id="rf0510"><person-group person-group-type="author"><name><surname>Nikolova</surname><given-names>K.A.</given-names></name><name><surname>Tchorbanov</surname><given-names>A.I.</given-names></name><name><surname>Djoumerska-Alexieva</surname><given-names>I.K.</given-names></name><name><surname>Nikolova</surname><given-names>M.</given-names></name><name><surname>Vassilev</surname><given-names>T.L.</given-names></name></person-group><article-title>Intravenous immunoglobulin up-regulates the expression of the inhibitory Fc gamma IIB receptor on B cells</article-title><source>Immunol Cell Biol</source><volume>87</volume><year>2009</year><fpage>529</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/icb.2009.36</pub-id><pub-id pub-id-type="pmid">19488062</pub-id></element-citation></ref><ref id="bb0515"><label>103</label><element-citation publication-type="journal" id="rf0515"><person-group person-group-type="author"><name><surname>S&#x000e9;it&#x000e9;</surname><given-names>J.-F.</given-names></name><name><surname>Guerrier</surname><given-names>T.</given-names></name><name><surname>Cornec</surname><given-names>D.</given-names></name><name><surname>Jamin</surname><given-names>C.</given-names></name><name><surname>Youinou</surname><given-names>P.</given-names></name><name><surname>Hillion</surname><given-names>S.</given-names></name></person-group><article-title>TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase</article-title><source>J Autoimmun</source><volume>37</volume><year>2011</year><fpage>190</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2011.05.014</pub-id><pub-id pub-id-type="pmid">21689906</pub-id></element-citation></ref><ref id="bb0520"><label>104</label><element-citation publication-type="journal" id="rf0520"><person-group person-group-type="author"><name><surname>Le Pottier</surname><given-names>L.</given-names></name><name><surname>Bendaoud</surname><given-names>B.</given-names></name><name><surname>Dueymes</surname><given-names>M.</given-names></name><name><surname>Daridon</surname><given-names>C.</given-names></name><name><surname>Youinou</surname><given-names>P.</given-names></name><name><surname>Shoenfeld</surname><given-names>Y.</given-names></name></person-group><article-title>BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer</article-title><source>J Clin Immunol</source><volume>27</volume><year>2007</year><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1007/s10875-007-9082-2</pub-id><pub-id pub-id-type="pmid">17393290</pub-id></element-citation></ref><ref id="bb0525"><label>105</label><element-citation publication-type="journal" id="rf0525"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>N.K.</given-names></name><name><surname>Papoff</surname><given-names>G.</given-names></name><name><surname>Zeuner</surname><given-names>A.</given-names></name><name><surname>Bonnin</surname><given-names>E.</given-names></name><name><surname>Kazatchkine</surname><given-names>M.D.</given-names></name><name><surname>Ruberti</surname><given-names>G.</given-names></name></person-group><article-title>Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway</article-title><source>J Immunol</source><volume>161</volume><year>1998</year><fpage>3781</fpage><lpage>3790</lpage><pub-id pub-id-type="pmid">9759905</pub-id></element-citation></ref><ref id="bb0530"><label>106</label><element-citation publication-type="journal" id="rf0530"><person-group person-group-type="author"><name><surname>Paquin Proulx</surname><given-names>D.</given-names></name><name><surname>Aubin</surname><given-names>E.</given-names></name><name><surname>Lemieux</surname><given-names>R.</given-names></name><name><surname>Bazin</surname><given-names>R.</given-names></name></person-group><article-title>Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg)</article-title><source>Clin Immunol</source><volume>135</volume><year>2010</year><fpage>422</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2010.01.001</pub-id><pub-id pub-id-type="pmid">20138586</pub-id></element-citation></ref><ref id="bb0535"><label>107</label><element-citation publication-type="journal" id="rf0535"><person-group person-group-type="author"><name><surname>S&#x000e9;&#x000ef;t&#x000e9;</surname><given-names>J.-F.</given-names></name><name><surname>Cornec</surname><given-names>D.</given-names></name><name><surname>Renaudineau</surname><given-names>Y.</given-names></name><name><surname>Youinou</surname><given-names>P.</given-names></name><name><surname>Mageed</surname><given-names>R.A.</given-names></name><name><surname>Hillion</surname><given-names>S.</given-names></name></person-group><article-title>IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes</article-title><source>Blood</source><volume>116</volume><year>2010</year><fpage>1698</fpage><lpage>1704</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-12-261461</pub-id><pub-id pub-id-type="pmid">20516366</pub-id></element-citation></ref><ref id="bb0540"><label>108</label><element-citation publication-type="journal" id="rf0540"><person-group person-group-type="author"><name><surname>Blanco-Melo</surname><given-names>D.</given-names></name><name><surname>Nilsson-Payant</surname><given-names>B.E.</given-names></name><name><surname>Chun Liu</surname><given-names>W.</given-names></name><name><surname>Uhl</surname><given-names>S.</given-names></name><name><surname>Hoagland</surname><given-names>D.</given-names></name><name><surname>M&#x000f8;ller</surname><given-names>R.</given-names></name></person-group><article-title>Imbalanced host response to SARS-CoV-2 drives development of COVID-19</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.026</pub-id><comment>In press</comment></element-citation></ref><ref id="bb0545"><label>109</label><element-citation publication-type="journal" id="rf0545"><person-group person-group-type="author"><name><surname>Kozicky</surname><given-names>L.K.</given-names></name><name><surname>Zhao</surname><given-names>Z.Y.</given-names></name><name><surname>Menzies</surname><given-names>S.C.</given-names></name><name><surname>Fidanza</surname><given-names>M.</given-names></name><name><surname>Reid</surname><given-names>G.S.D.</given-names></name><name><surname>Wilhelmsen</surname><given-names>K.</given-names></name></person-group><article-title>Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state</article-title><source>J Leukoc Biol</source><volume>98</volume><year>2015</year><fpage>983</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1189/jlb.3VMA0315-078R</pub-id><pub-id pub-id-type="pmid">26216934</pub-id></element-citation></ref><ref id="bb0550"><label>110</label><element-citation publication-type="journal" id="rf0550"><person-group person-group-type="author"><name><surname>Meregalli</surname><given-names>C.</given-names></name><name><surname>Marjanovic</surname><given-names>I.</given-names></name><name><surname>Scali</surname><given-names>C.</given-names></name><name><surname>Monza</surname><given-names>L.</given-names></name><name><surname>Spinoni</surname><given-names>N.</given-names></name><name><surname>Galliani</surname><given-names>C.</given-names></name></person-group><article-title>High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats</article-title><source>J Neuroinflammation</source><volume>15</volume><year>2018</year><fpage>232</fpage><pub-id pub-id-type="doi">10.1186/s12974-018-1270-x</pub-id><pub-id pub-id-type="pmid">30131066</pub-id></element-citation></ref><ref id="bib551"><label>111</label><element-citation publication-type="journal" id="opt0X4w05JvlG"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Bin</given-names></name><name><surname>Liu</surname><given-names>Shuyi</given-names></name><name><surname>Tan</surname><given-names>Tan</given-names></name><name><surname>Huang</surname><given-names>Wenhui</given-names></name><name><surname>Dong</surname><given-names>Yuhao</given-names></name><name><surname>Chen</surname><given-names>Luyan</given-names></name></person-group><article-title>Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection</article-title><source>Chest</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.chest.2020.03.039</pub-id><comment>In press</comment></element-citation></ref><ref id="bib552"><label>112</label><element-citation publication-type="journal" id="optwoLMryvKbT"><person-group person-group-type="author"><name><surname>Rajendran</surname><given-names>Karthick</given-names></name><name><surname>Narayanasamy</surname><given-names>Krishnasamy</given-names></name><name><surname>Rangarajan</surname><given-names>Jayanthi</given-names></name><name><surname>Rathinam</surname><given-names>Jeyalalitha</given-names></name><name><surname>Natarajan</surname><given-names>Murugan</given-names></name><name><surname>Ramachandran</surname><given-names>Arunkumar</given-names></name></person-group><article-title>Convalescent plasma transfusion for the treatment of COVID&#x02010;19: Systematic review</article-title><source>J Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25961</pub-id><comment>In press</comment></element-citation></ref></ref-list><ack id="ac0005"><title>Acknowledgements</title><p>The authors thank all the members of the CREA and the &#x0201c;CP-Covid-19 Group&#x0201d; for contributions and fruitful discussions.</p></ack></back></article>